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La distrofia miotónica (DM) es la forma más común de distrofia muscular en 
adultos (Giovanni Meola and Cardani 2015). La DM es una enfermedad genética 
de herencia dominante que se caracteriza por manifestaciones multisistémicas 
tales como.miotonía progresiva, degeneración muscular preferentemente 
distal, cataratas de inicio temprano (menores de 50 años), defectos de 
conducción cardíaca, cambios en los parámetros neuropsicológicos y trastornos 
endocrinos (Harper 2001; Ashizawa and Sarkar 2011). La esperanza de vida de 
los pacientes con la forma más típica de la enfermedad está fuertemente 
reducida. Con base en la determinación clínica, la prevalencia mundial de DM 
se estimó en 1/8000, y en Europa, la prevalencia es 1/20000 (Harper 2001; Udd 
and Krahe 2012). 
Actualmente se conocen dos tipos genéticamente distintos de DM. Distrofia 
miotónica tipo 1 (DM1; OMIM #160900) y distrofia miotónica tipo 2 (DM2; 
OMIM #602668). Ambos tipos son trastornos basados en la expansión de 
microsatélites en regiones no codificantes que afectan a diferentes genes. La 
entidad clínica de DM1 fue reconocida por primera vez por Steinert (Steinert 
1909) y Batten y Gibb (Batten and Gibb 1909) en 1909. La DM1 es causada por 
una expansión de repeticiones de trinucleótidos CTG inestables en la región 3' 
no traducida (UTR) del gen de la proteína kinasa de la distrofia miotónica 
(DMPK; OMIM 605377) en la posición cromosómica19q13.3 (Brook et al. 1992; 
Fu et al. 1992; M. Mahadevan et al. 1992). Posteriormente, se identificó a otro 
grupo de pacientes en 1994 con un transtorno multisistémico diferente. Se 
describió con miotonía hereditaria dominante, debilidad muscular más 
proximal que distal y cataratas, pero sin el defecto del gen responsable de la 
enfermedad de Steinert (Ricker 1999; C A Thornton, Griggs, and Moxley 1994; 
G Meola and Sansone 1996; Udd et al. 1997). Esta enfermedad se denominó 
miopatía miotónica proximal (PROMM, OMIM*160900)(Ricker 1999) o distrofia 
miotónica tipo 2 (DM2) (C A Thornton, Griggs, and Moxley 1994). El tipo 2 de 
DM es causado por una expansión inestable del tetranucleótido CCTG en el 
intrón 1 del gen CCHC-type zinc finger nucleic acid-binding protein (CNBP) 





posición cromosómica 3q21.3 [Fig. I1](Ranum et al. 1998; Liquori et al. 2001; 
Bachinski et al. 2009). 
 
Fig. I1. Representación esquemática de las mutaciones causantes de DM: (A) En el caso de DM1, 
la mutación genética es la expansión de una repetición de CTG en la región 3 'UTR del exón 15 del 
gen DMPK. En la figura, está representado por el cuadro naranja. La región flanqueante a DMPK 
contiene los genes DMDW y SIX 5 (recuadro azul y el amarillo, respectivamente). (B) En el caso de 
DM2, la expansión de CCTG está presente en el primer intrón del gen CNBP que se representa con 
una caja amarilla. 
En DM1, el número de repeticiones CTG en el gen DMPK es variable en la 
población general, estimándose entre 5 y 37 repeticiones. En pacientes con 
DM1, el tamaño de la repetición varía y longitudes entre 50 y 4000 (150-12.000 
bp) se asocian con la enfermedad sintomática (Giovanni Meola and Cardani 
2015). Longitudes de repeticiones de 38-50 se consideran alelos de 
premutación, mientras que 51-100 repeticiones se conocen como 
protomutaciones. Las mutaciones de expansiones CTG muestran dos 
fenómenos importantes. El primero es el mosaicismo somático, presentando 
una inestabilidad y variación en el tamaño de la expansión de las repeticiones 
dependiendo de diferentes tipos de tejidos y células (Morales et al. 2012; 
Higham et al. 2012). El segundo es la anticipación genética, donde el tamaño de 





enfermedad tiene una manifestacion clinica más garve. En CNBP, los individuos 
normales llevan menos de 26 repeticiones mientras que los alelos con 27-74 
repeticiones se consideran como una “zona gris”, ya que tienen una asociación 
poco clara con la enfermedad (Kamsteeg et al. 2012). El tamaño patogénico más 
pequeño informado varía entre 55-75 CCTG pero puede llegar hasta 
aproximadamente 11,000 repeticiones en pacientes con DM2 (Liquori et al. 
2001; Bachinski et al. 2009; Giovanni Meola and Cardani 2017). Al igual que las 
mutaciones de repetición CTG, el tamaño de las expansiones CCTG parece 
aumentar con el tiempo y estas repeticiones son inestables en las células 
somáticas. Contrariamente a DM1, en DM2, la anticipación no se ha observado. 
Por otra parte, DM2 se considera menos grave que DM1 (Giovanni Meola and 
Cardani 2017) y generalmente las expansiones de CCTG se contraen en la 
siguiente generación (Day et al. 2003). El espectro clínico de DM es 
extremadamente amplio, diverso y puede variar entre ambos tipos. En 
comparación con DM1, DM2 es clínicamente más leve y progresa más 
lentamente que DM1. En este sentido, en un informe reciente, se describe la 
participación de la proteína rbFOX como amortiguador del efecto de las 
repeticiones CCUG in vivo (Chantal S. et al. 2018). En la tabla I1 se comparan 
diferentes síntomas clínicos de ambos tipos de la enfermedad. Clínicamente, la 
DM1 es más diversa y contiene cuatro subtipos diferentes que pueden aparecer 
en diferentes etapas de la vida y pueden tener diferentes longitudes de 
repeticiones según el subtipo. En la Tabla I2, los diferentes subtipos DM1 se 
enumeran con sus respectivas longitudes medias de repetición y características 
cardinales asociadas (De Antonio et al. 2016; Yum, Wang, and Kalsotra 2017). 
Entre todos los subtipos de DM1, el de inicio en el adulto y el de inicio congénito 
son los subtipos más prevalentes y graves DM1, respectivamente (Harper 2001; 





Tabla 1: Diferencias clínicas entre DM1 y DM2 
 
Características clínicas DM1 DM2 
Herencia Dominante Dominante 
Defecto genético Cromosoma 19; expansion CTG en el 
3'UTR del gen DMPK 
Cromosoma 3; Expansión de 
CCTG en el intrón 1 del gen 
CNBP 
Edad de inicio Infancia a la edad adulta Infancia hasta la edad adulta 
avanzada 
Forma congénita Presente Ausente 
Cataratas Presente Presente 
Músculo esquelético 
Debilidad muscular Incapacitante a los 50 años Inicio después de los 20-40 
años 
Dolor muscular Ausente o leve Incapacitante en muchos 
Miotonía clínica Evidente en el comienzo del adulto Presente en ˂50% 
Miotonía EMG Siempre presente Ausente o variable en 
muchos 
Cerebro 
Trastornos del sueño Presente Infrecuente 
Deterioro cognitivo Prominente No es aparente 
Problemas del SNC 
en la infancia 
Frecuentemente presente Ausente 
Arritmia cardíaca Presente De    ausente    a    grave    en 




Anticipación Siempre presente Presente excepcional y solo 
clínico 
Esperanza de vida Reducida Normal 






Tabla I2: Resumen de fenotipos clínicos en subtipos DM1 y su correlación con el tamaño de repeticiones 
CTG 








anticipación (Sí / 
No) 
Premutación Ninguno 38-49 - Normal - 





dismorfia facial, disfagia 







Síntomas similares a la 
DM1 congénita pero 
menos grave 









debilidad y   desgaste 
muscular,   cataratas, 
hipogonadismo masculino, 
resistencia a la insulina, 
problemas  cognitivos, 
disfunción  ventricular 
izquierda 
250–750 20–40 Reducida Penetrancia 
completa 
Sí 
Incio Juvenil Síntomas similares a DM1 
en adultos pero más 
graves 
400–800 10–20 Acortado Penetrancia 
completa 
Sí 
Inicio tardío Cataratas, hipersomnia, 
miotonía 
100–600 >40 año Normal Penetrancia 
completa 
Sí 
Adaptado de De Antonio M. et al., 2016; Yum K. et al., 2017. 
 
 
Manifestaciones cardíacas en DM: 
 
Aproximadamente el 80% de los pacientes con DM1 desarrollarán enfermedad 
cardíaca en sus vidas, pero el riesgo de enfermedad cardíaca es más 
pronunciado en pacientes jóvenes (2-30 años) que en los ancianos (Lund et al. 
2014). De hecho, las complicaciones cardíacas representan el 30% de las 
muertes de los pacientes y son la segunda causa más importante de fatalidades 
después de la insuficiencia respiratoria (Mathieu et al. 1999; Mankodi and 
Thornton 2002; Pelargonio et al. 2002). Se observan tres fenotipos cardíacos 
interrelacionados en individuos con DM1. 
• El primero son los defectos de conducción, que son particularmente 





al. 1988). Estos defectos son el resultado de la degeneración del sistema de 
conducción cardíaca y son causados principalmente por la fibrosis 
miocárdica (Petri et al. 2014). La fibrosis miocárdica se debe a la hipertrofia 
de los miocitos, a la infiltración grasa focal y también a la infiltración 
linfocítica (Nguyen et al. 1988; McNally and Sparano 2011). Las alteraciones 
de la conducción son prevalentes y afectan al 40% de los pacientes con DM1 
(Groh et al. 2008) 65% de los pacientes tiene un ECG anormal y las 
anormalidades típicas de ECG incluyen la prolongación del intervalo PR 
[período que se extiende desde el inicio de la despolarización auricular 
hasta el comienzo de la despolarización ventricular también conocido como 
complejo QRS] (˃240 ms; 20-40% de pacientes) y la duración del QRS (˃120 
ms; 5-25% DM1 patients) (Lau et al. 2015). 
• El segundo fenotipo cardíaco es el desarrollo de arritmias ventriculares y / 
o auriculares potencialmente fatales (Nigro, Papa, and Politano 2012; 
Benhayon et al. 2015). Las alteraciones de la conducción proporcionan un 
sustrato para el bloqueo de la conducción, la actividad ectópica y las 
arritmias reentrantes. Estas alteraciones pueden causar palpitaciones, 
síncope y muerte súbita cardíaca (Finsterer and Stöllberger 2012). 
Alrededor del 25% de los pacientes con DM1 muestran taquiarritmias 
auriculares (supraventriculares), específicamente fibrilación auricular y 
aleteo auricular (Pelargonio et al. 2002; Groh et al. 2008). Las arritmias 
ventriculares son menos comunes pero más graves y se consideran la 
principal causa de muerte súbita (Hermans et al. 2012; Bienias et al. 2017). 
• El tercer fenotipo, aunque más raro, es la disfunción diastólica y / o sistólica 
mecánica que puede progresar a un fallo sistólico y diastólico combinado 
(Phillips and Harper 1997; Mathieu et al. 1999; Lazarus et al. 2002). La 
disfunción ventricular es más común, sin embargo, la dilatación auricular 
izquierda también puede ocurrir en el curso de la enfermedad (McNally and 
Sparano 2011). Otras manifestaciones cardíacas asociadas incluyen 
cardiopatía isquémica, en forma de angina (tanto estable como inestable) e 
infarto de miocardio. Los estudios de ECG también han encontrado que 
algunos individuos con DM1 tienen contractilidad del corazón reducida, 
como lo revela una fracción de eyección del ventrículo izquierdo inferior al 





algunos pacientes con DM1 también se observó insuficiencia pulmonar 
(Schmacht et al. 2016). 
En comparación con DM1, los problemas cardíacos en DM2 se 
consideraon menos graves y frecuentes (G. Meola et al. 2002; Flachenecker et 
al. 2003; Sansone et al. 2007). Sin embargo, estudios recientes indican que el 
riesgo general de enfermedad cardíaca en pacientes con DM2 es muy cercano 
al de los pacientes con DM1 (Giovanni Meola and Cardani 2017). Al igual que en 
DM1, las características cardíacas en DM2 incluyen defectos de conducción AV, 
arritmias y cardiomiopatía dilatada (T. M. Lee et al. 2012). La lesión miocárdica 
subclínica causa defectos de conducción y se correlaciona directamente con las 
anomalías del ECG encontradas en pacientes con DM2 (Schmacht et al. 2016). 
Los defectos de conducción también causan arritmias cardíacas graves y muerte 
súbita en pacientes con DM2 (Wahbi et al. 2009). A diferencia de DM1, los 
pacientes con DM2 no muestran insuficiencia pulmonar (Schmacht et al. 2016). 
Patogénesis molecular: 
 
Tanto DM1 como DM2 comparten un complejo mecanismo de fisiopatología. 
Las mutaciones encontradas en ambos tipos, que contienen expansiones CTG o 
CCTG, se transcriben y procesan en mRNA poliadenilados y procesados. Los RNA 
mutantes forman una estructura secundaria y se acumulan formando foci 
ribonucleares. El RNA mutante interfiere con proteínas de unión a RNA que 
actúan en trans, lo que conduce a cantidades aumentadas del primer miembro 
de la familia CUGBP / Elav (CELF1) y actividad reducida de las proteínas 
Muscleblind-like (MBNL) (Osborne and Thornton 2006; Klein, Gasnier, and 
Furling 2011; Fernandez-Costa et al. 2011). En el núcleo, la actividad de las 
proteínas MBNL (MBNL1-3 en vertebrados, Muscleblind en Drosophila) se ve 
disminuida debido a su secuestro en foci ribonucleares (Miller et al. 2000; Kino 
et al. 2004; Mankodi et al. 2001; Fardaei et al. 2002; Jiang et al. 2004; Cardani 
et al. 2006; LukáŠ et al. 2012). Por su parte los niveles de CELF1 se regulan 
positivamente mediante hiperfosforilación a través de diferentes quinasas de 
señalización (Kuyumcu-Martinez, Wang, and Cooper 2007; Salisbury et al. 2008; 
Jin et al. 2009; Huichalaf et al. 2010). La sobreexpresión cardíaca específica de 
CUGBP1 reproduce anomalías moleculares y funcionales de la distrofia 
miotónica tipo 1 (Kim et al. 2014). Estas dos proteínas juntas regulan múltiples 





traducción, poliadenilación, biogénesis de miRNA, estabilidad de mRNA y 
localización intracelular de mRNA (J. E. Lee and Cooper 2009; Batra et al. 2014; 
Giovanni Meola 2013; Rau et al. 2011; Adereth et al. 2005; E. T. Wang et al. 
2012, 2015; Konieczny et al. 2017). Por lo tanto, en DM, la pérdida de función 
de MBNL por secuestro, combinada con la sobreexpresión de CELF1, conduce a 
la reprogramación del procesamiento del RNA hacia un patrón embrionario. Se 
han descrito a fondo y se han relacionado con síntomas específicos de la 
enfermedad varios defectos de procesamiento alternativo de pre-mRNAs 
concretos (Mankodi and Thornton 2002; Savkur, Philips, and Cooper 2001; Tang 
et al. 2012; Fugier et al. 2011; Freyermuth et al. 2016). Por ejemplo, el 
procesamiento incorrecto de CLCN1, el canal de calcio CaV1.1 y el receptor 
insulina (IR) causa diferentes fenotipos de la enfermedad, como miotonía, 
debilidad muscular y resistencia a la insulina, respectivamente (Charlet-B. et al. 
2002; Tang et al. 2012; Savkur, Philips, and Cooper 2001). 
Además de las alteraciones de procesamiento alternativo, se han descrito otros 
mecanismos moleculares alterados en la progresión de la enfermedad. La 
redistribución o lixiviación inapropiada del factor de transcripción SP1 
(Ebralidze et al. 2004) y la localización errónea del factor de transcripción SPEN 
(también conocido como SHARP) que se han observado en DM, se han 
relacionado con cambios en las concentraciones en el estado estacionario de 
varias moléculas de mRNA (Dansithong et al. 2011). La downregulación de 
microRNAs ha sido también implicada en ambos tipos de DM (Perbellini et al. 
2011; Rau et al. 2011). En un estudio, se ha demostrado que MEF2, que está 
disminuído en el corazón de ratones modelo de DM1, regula microRNAs 
específicos del corazón, lo cual podría contribuir a la disfunción cardíaca 
específica de DM1 (Kalsotra et al. 2014). El papel de CUGBP1 también parece 
relevante en los fenotipos cardiacos DM1. La sobreexpresión de CUGBP1 
humano en corazón de ratón adulto reprodujo cambios funcionales, 
electrofisiológicos y moleculares como se observó en pacientes con DM1 
(Koshelev et al. 2010). Los estudios funcionales demostraron que la inhibición 
de PKC mejoró los defectos de conducción cardíaca y las anomalías de 
contracción encontradas en este modelo de ratón. El inhibidor también redujo 
la mala regulación de los eventos de corte y empalme regulados por CUGBP1, 
pero no los regulados por MBNL1, lo que sugiere papeles distintos para estas 





embargo, las consecuencias fisiológicas combinadas de las alteraciones en el 
procesamiento alternativo, la expresión génica y las alteraciones de miRNAs en 
el corazón aún no se han aclarado (Fernandez-Costa et al. 2013; Kalsotra et al. 
2014; E. T. Wang et al. 2015). En los últimos años, el descubrimiento de la 
traducción no-AUG asociada a las repeticiones (RAN) (Cleary and Ranum 2014; 
Zu et al. 2017) en las enfermedades neurodegenerativas causadas por 
microsatélites, ha abierto la posibilidad de que también este mecanismo 
contribuya a las diferentes disfunciones sistémicas observadas en la DM. Sin 
embargo, esto aún no se ha establecido. 
Modelos animales para estudiar la disfunción cardíaca en DM: 
 
A pesar de la relevancia de la afectación cardiaca en la DM, existen muy pocos 
modelos animales disponibles para estudiar los mecanismos moleculares que la 
causan. Los ratones transgénicos conocidos como DMSXL (Huguet et al. 2012) y 
GFP-DMPK-(CTG) 5 (M. S. Mahadevan et al. 2006) son los únicos modelos 
disponibles para estudiar el efecto de las repeticiones en el desempeño del 
corazón. Estos ratones, sin embargo, tienen algunas limitaciones. Los ratones 
DMSXL reproducen las principales características clínicas observadas en la 
enfermedad humana, incluida la fuerza muscular reducida, menor rendimiento 
motor y deficiencias respiratorias. Sin embargo, para observar fenotipos 
cardiacos en los ratones DMSXL es necesario tratarlos con el agente 
antiarrítmico de clase I flecainida (Algalarrondo et al. 2015). Por su parte, los 
ratones GFP-DMPK- (CTG) 5 muestran toxicidad dentro del rango normal de 5 
repeticiones CTG en ausencia de foci ribonucleares y tienen una alta tasa de 
mortalidad. 
Drosophila como alternativa a los modelos de ratón para estudiar la 
disfunción cardíaca: 
El corazón de Drosophila melanogaster exhibe notables similitudes con el de los 
vertebrados en términos de origen morfogenético, estructura y mecanismos de 
regulación del desarrollo. Tanto en Drosophila como en embriones de 
vertebrados, el corazón se origina en dos hileras bilateralmente simétricas de 
células mesodérmicas que migran distalmente desde el punto de invaginación 
durante la gastrulación, se especifican como tejido cardíaco y finalmente se 





subsecuente de bucles y septos dota al corazón de múltiples cámaras en 
vertebrados, mientras que el corazón de Drosophila permanece tubular, 
aunque dividido por una válvula intracardíaca en una estructura anterior 
estrecha, llamada aorta, y una estructura posterior pulsátil de 1 mm, conocida 
como vaso dorsal o corazón (Ocorr, Vogler, and Bodmer 2014). La estructura y 
fisiología simple del tubo del corazón de la mosca proporcionan un sistema de 
ensayo in vivo adecuado para estudiar las disfunciones cardíacas (Fig. I2 A). 
Las ventajas de la genética de invertebrados se han utilizado para 
estudiar el desarrollo cardíaco y desarrollar modelos de enfermedades 
humanas en la mosca. La principal herramienta genética de Drosophila es la 
capacidad de dirigir la expresión de un transgén dado a prácticamente cualquier 
tejido de mosca y a cualquier tiempo de desarrollo. Las moscas transgénicas se 
pueden obtener en un periodo de tiempo de 6-8 semanas. La expresión 
transgénica en la mosca se logra generalmente usando el sistema binario Gal4- 
Upstream Activating Sequence (UAS) derivado del control del metabolismo de 
la galactosa en la levadura (Brand and Perrimon 1993). En las moscas Gal4, la 
expresión específica de tejido del factor de transcripción Gal4 de levadura se 
consigue colocándole promotores específicos de tejido aguas arriba del mismo, 
mientras que las moscas UAS llevan transgenes de interés aguas abajo de una 
secuencia UAS específica. Típicamente, se cruza una linea Gal4 con un promotor 
específico con líneas de genes diana UAS y se examinan los efectos de la 
expresión génica específica de tejido en la progenie. Por ejemplo, en la 
descendencia F1, Hand-Gal4 dirige la expresión del transgén UAS al mesodermo 
cardiogénico embrionario (Han 2005) mientras que tinC-Gal4 impulsa la 
expresión de transgenes en cardioblastos (Lo and Frasch 2001). Una versión 
mejorada del controlador tinC-Gal4 es la GMH5-Gal4, que permite la expresión 
temprana en cardiomiocitos impulsada por un enhancer de tinman de 900 nt y 
mantiene la expresión a través de un bucle autorregulador UAS-Gal4 (Fig. I2 B) 








Fig. I2: Representación esquemática del corazón de la mosca y el sistema Gal4-UAS: (A) 
Representación esquemática del corazón de Drosophila o vaso dorsal (Wolf and Rockman 2011). 
El corazón se extiende desde el segmento abdominal A2 hasta A6. La cámara cónica está ubicada 
al comienzo del vaso dorsal. Los ostia, que son las aperturas en el corazón, ayudan a redistribuir 
la hemolinfa del corazón a la cavidad del cuerpo. Los músculos alares conectan el corazón con la 
cutícula. 
Estrategias terapéuticas experimentales: 
 
Hasta ahora, no está disponible para la DM ningún tratamiento efectivo , pero 
varios enfoques han sido probados experimentalmente en modelos de DM in 
vivo e in vitro. Se han desarrollado varias herramientas terapéuticas nuevas con 
el objetivo de abordar diferentes procesos de la fisiopatología de la DM que 
incluyen: (1) silenciamiento transcripcional, (2) silenciamiento 
postranscripcional, (3) inhibición de interacciones entre MBNL y RNA tóxico, o 
(4) rutas alteradas aguas abajo del RNA tóxico [Fig. I3] (Charles A Thornton, 







Fig I3: Diferentes estrategias para tratar la distrofia miotónica (Tomado de Thorton C.A. et al., 
2017) 
En los últimos años, las pruebas de concepto terapéuticas se han centrado en 
dirigirse a la parte más aguas arriba de la patología de DM para bloquear el 
comienzo de la cascada tóxica. Aunque la inhibición de la transcripción no se 
considera una estrategia general robusta para tratar las mutaciones de ganancia 
de función, existen informes de diferentes compuestos que pueden reducir la 
expresión de las repeticiones tóxicas a través de la inhibición de la transcripción. 
Por ejemplo, en Coonrod et al. han demostrado que la pentamidina y los 
antibióticos relacionados se pueden unir a las repeticiones CTG.CAG y reducir la 
expresión del RNA con repeticiones CUG (Coonrod et al. 2013). 
En el caso de DM1, se han usado varias tecnologías basadas en 
oligonucleótidos (por ejemplo, oligonucleótidos antisentido - ASO) para destruir 
el RNA tóxico a nivel postranscripcional. Por ejemplo, los ASO que activan RNasa 
H1 causan una reducción marcada del RNA con CUGs en el músculo esquelético, 
la liberación de proteína MBNL de foci, la corrección de errores de 
procesamiento, la eliminación de miotonía y la mejora de la fisiología muscular 
(Wheeler et al. 2012). Varios hallazgos estimularon los esfuerzos para 
desarrollar un ASO optimizado para DMPK y en diciembre de 2014 se lanzó la 
primera fase de un ensayo clínico utilizando estos ASO optimizados (gapmer- 
ASO) con el objetivo de destruir los transcritos de DMPK en los músculos 





Varios grupos han seguido un enfoque alternativo para tratar los 
fenotipos relacionados con la enfermedad utilizando el diseño racional o 
rastreos de alto rendimiento para identificar moléculas pequeñas que regulan 
positivamente MBNL1 e inhiben la interacción MBNL: CUGexp o dispersan los foci 
de RNA(Ketley et al. 2014; Garcia-Lopez et al. 2011; Rzuczek, Southern, and 
Disney 2015; Nakamori et al. 2016; Cerro-Herreros et al. 2016). En comparación 
con los ASO, este enfoque es cada vez más favorable para el desarrollo de 
fármacos, ya que los ASO presentan dificultades en su distribución al músculo. 
Otra estrategia terapéutica es dirigirse a las vías de señalización que se 
activan después de la expresión de CUGexp. Estas vías aguas abajo incluyen la 
proteína quinasa C (PKC), la glucógeno sintasa quinasa 3 beta (GSK3beta) y la 
proteína quinasa activada por AMP (AMPK)/ mTOR (Charles A Thornton, Wang, 
and Carrell 2017). La inhibición de PKC por moléculas pequeñas conduce a la 
normalización de los niveles alterados de proteína CELF, rescatando el fenotipos 
cardíacos en modelos de ratón (G. S. Wang et al. 2009). Recientemente, la 
normalización de la vía AMPK / TOR mediante la administración de 5- 
aminoimidazol-4-carboxamida ribonucleótido (AICAR), un activador de AMPK o 
rapamicina, un inhibidor de mTOR, redujo el tiempo de relajación muscular 
después de la estimulación tetánica en DM1 (Brockhoff et al. 2017). En los 
últimos tiempos, Tideglusib, un inhibidor de GSK-3 se está estudiando en 
ensayos clínicos de Fase II como tratamiento para la DM1 congénita / juvenil 



































Aunque algunos modelos murinos están disponibles para investigar las 
complicaciones cardíacas en DM, el complicado manejo de estas líneas 
por su baja tasa reproductiva y reducida longevidad, y el hecho de que 
solo presenten fenotipos cardiacos al ser expuestas a ciertas drogas o a 
condiciones de estrés, desaconseja su uso para conocer la causa 
molecular de los fenotipos cardiacos en DM. 
Además de los diferentes modelos en ratón, en el campo de la DM, varios 
investigadores han desarrollado moscas transgénicas varias líneas de 
Drosophila para imitar los fenotipos multisistémicos, p.ej. en los 
músculos y los ojos. Además, se ha demostrado previamente en la 
literature que los moscas modelos también se pueden utilizar para 
comprender diferentes alteraciones cardiacas que se producen en 
humanos debido a la elevada similitud con el desarrollo del corazón 
humano. 
Por lo tanto, el objetivo de este estudio fue generar y caracterizar 
modelos en Drosophila de disfunción cardiaca en DM para dilucidar los 
mecanismos patogénicos moleculares y testar moléculas que puedan 
revertirla. Para cumplir con el objetivo general de este estudio nos 
propusimos los siguientes objetivos específicos: 
Objetivo 1: Estudio de la fisiopatología y las alteraciones moleculares 
relacionadas con la disfunción cardíaca producida al expresar 
repeticiones CTG expandidas en el corazón de Drosophila. 
Objetivo 2: Estudio de las alteraciones cardiacas producidas al expresar 
las repeticiones CCTG en el corazón de Drosophila y su comparación con 
las producidas por la expression de repeticiones CTGs. 
Objetivo 3: Testar el potencial terapéutico de diferentes candidatos 
químicos sobre el fenotipo de disfunción cardiaca en DM. 
Objetivo 4: Caracterización del papel de diferentes modificadores 




































La sección de resultados principales incluye trabajos de tres artículos publicados 
que describen la generación y caracterización de fenotipos cardiacos en 
modelos en Drosophila de disfunción cardiaca en DM1 y DM2 y posibles 
estrategias terapéuticas para rescatar estos fenotipos. Para obtener modelos 
adecuados de ambos tipos de fenotipos cardiacos DM en moscas, se generaron 
líneas de moscas transgénicas UAS-CTG y UAS-CCTG que portaban 250 CTG o 
1100 repeticiones puras no codificantes de CCTG, respectivamente 
(Chakraborty et al. 2015; Cerro-Herreros et al. 2017). Estas expansiones se 
encuentran dentro del rango patológico de repeticiones e imitan el tamaño de 
expansión al menos 4 veces mayor en pacientes con DM2 en comparación con 
DM1 (Schoser and Timchenko 2010; Warf and Berglund 2007). Como controles, 
se generaron moscas con 20x repeticiones. Las líneas de moscas UAS se 
cruzaron con moscas GMH5-Gal4 que promovían la expresión específica en 
corazón de las repeticiones (Wessells and Bodmer 2004). Este cepa también 
incluía el reportero UAS-GFP, que permite el marcaje de los tejidos en los que 
se expresa Gal4. Las moscas F1 que expresan repeticiones en el corazón se 
analizaron a varios niveles para caracterizar fenotipos relacionados con la DM. 
1. Caracterización de la toxicidad de C(C)UG en el corazón de Drosophila: 
 
Esta sección incorpora mi trabajo publicado en dos artículos (Chakraborty et 
al. 2015 y Cerro-Herreros et al. 2017). En estos trabajos se describe en detalle 
el efecto de la expresión de las repeticiones expandidas CTG y CCTG en el 
corazón de la mosca. En concreto, en el manuscrito Cerro-Herreros et al. 2017 
del que soy co-primera autora, mi contribución se centró en describir el 
modelo de disfunción cardiaca en DM2. 
1.1 La expresión de expansiones C(C)UG produce el secuestro de Muscleblind 
en el corazón de mosca y altera eventos de procesamiento alternativo 
dependientes de Muscleblind: 
A nivel molecular, se ha demostrado que las proteínas MBNL están secuestradas 
en foci ribonucleares y juegan un papel crucial en la manifestación de la 
enfermedad. En nuestros estudios, hemos demostrado por primera vez la 
presencia de Muscleblind en el corazón de la mosca. En moscas control, 





en cardiomiocitos adultos, se detectó claramente. Inmunohistoquímica con un 
anticuerpo anti-Muscleblind (Houseley et al. 2005) muestra una expresión 
difusa de Muscleblind tanto en el núcleo como en el citoplasma de los 
cardiomiocitos de la mosca (Chakraborty et al. 2015). La hibridación 
fluorescente in situ (FISH) seguida de inmunofluorescencia reveló que, tras la 
expresión de repeticiones expandidas de CUG o CCUG en las células del corazón, 
Muscleblind quedaba secuestrada en foci ribonucleares. Por el contrario, las 
moscas que expresan un tamaño de repeticiones en el rango no patológico 
tanto en el caso de las repeticiones CUG como en las CCUG no mostraron ningún 
foci o acumulación de Muscleblind (Chakraborty et al. 2015; Cerro-Herreros et 
al. 2017). De acuerdo con la literatura, el secuestro de Muscleblind conduce a 
errores en el procesamiento alternativo de varios transcritos, lo cual origina 
fenotipos de la enfermedad. En los corazones de moscas modelo que expresan 
repeticiones largas, la inclusión del exón 13 del gen Serca y el exón 16´ del gen 
Fhos se encontraron alterados significativamente. Estos datos confirmaron que 
el secuestro de Muscleblind en foci ribonucleares observado en corazones de 
moscas DM1 y DM2 conduce a una reducción funcional de la proteína en el 
tejido cardíaco adulto (Cerro-Herreros et al. 2017). 
1.2 La expresión de repeticiones expandidas en el corazón de Drosophila 
induce la autofagia: 
 
Se ha demostrado previamente que la expresión de repeticiones largas de CTG 
induce la activación patológica de autofagia causando atrofia muscular en las 
moscas. Entre los diferentes genes relacionados con la autofagia, se encontró 
que la expresión de Atg4, Atg7 y Atg12 están significativamente aumentados en 
los músculos de la mosca que expresan repeticiones (Bargiela et al. 2015). La 
expresión de estos genes también se encontró aumentada en el caso de que las 
repeticiones expandidas de CUG o CCUG se dirigieran al corazón de Drosophila, 
en comparación con las moscas control que expresan GFP o las repeticiones 
cortas (Cerro-Herreros et al. 2017). Estos datos sugerían, por primera vez, un 
papel potencial de la desregulación de la vía de la autofagia en la disfunción 
cardíaca de DM tras la expresión de repeticiones expandidas. Curiosamente, la 
expresión de repeticiones CCUG largas en el corazón provoca una regulación al 
alza más fuerte de los factores relacionados con la autofagia que las 





dependientes del tejido que pueden modular la toxicidad de las repeticiones 
CUG y CCUG. Sin embargo, todavía falta la conexión mecanística entre la 
autofagia y los defectos cardíacos en las moscas. Para comprender la relación 
entre la activación de diferentes genes de la autofagia y los parámetros 
cardíacos, esta regulación al alza debe confirmarse detectando la presencia de 
lisosomas y alteraciones en las otras vías aguas abajo. 
1.3 La expresión de repeticiones CUG o CCUG expandidas en el corazón de la 
mosca reduce la supervivencia y altera el rendimiento cardíaco: 
Estudios poblacionales han encontrado tasas más altas de mortalidad y 
morbilidad, y una correlación positiva entre la edad al inicio y la edad al 
momento de la muerte, en individuos afectados por DM (Breton and Mathieu 
2009). Como resultado de la expresión de repeticiones CUG o CCUG expandidas 
en el corazón, la supervivencia media y la vida máxima en las moscas modelo 
también se redujeron significativamente (casi a la mitad) en comparación con 
los controles mantenidos a 29°C (Chakraborty et al. 2015; Cerro-Herreros et al. 
2017). Este hallazgo en archivos DM1 se correlaciona con informes de humanos 
afectados (Breton and Mathieu 2009; Petri et al. 2012). Es de destacar que la 
curva de supervivencia de las moscas que expresan repeticiones cortas de CUG 
o CCUG fue similar a la de las moscas control. 
Para estudiar la función cardíaca, corazones de moscas adultas de 1 semana de 
edad fueron disecados en hemolinfa artificial y grabados con una cámara de 
video digital. Las grabaciones de video se analizaron usando un método 
semiautomático de análisis óptico del ritmo cardíaco (SOHA) para cuantificar los 
diferentes parámetros funcionales del corazón. Los trazados en M-mode 
obtenidos a partir de los clips de película proporcionaron detalles de las 
posiciones de los bordes de la pared del corazón (eje y) a lo largo del tiempo 
(eje x), ilustrando la ritmicidad y la dinámica de las contracciones del corazón 
(Ocorr, Akasaka, and Bodmer 2007). El proceso lo describimos en detalle en una 
publicación en la revista electrónica “Protocols Exchange” (Selma-Soriano et al. 
2018). El M-mode permite la cuantificación de los siguientes parámetros 
cardiacos: fase de relajación y contracción (DI, y SI, por intervalo diastólico y 
sistólico), período cardíaco (HP, equivalente a intervalo diastólico más sistólico), 
índice de arritmia (AI; obtenido al dividir la desviación estándar del HP por su 





porcentaje de acortamiento fraccional (%FS, FS = EDD - ESD / EDD × 100), que 
es una medida de la contractilidad del corazón. Usando este enfoque, se ha 
observado que la expresión de ambas repeticiones CUG o CCUG en 
cardiomiocitos causa alteraciones en diferentes parámetros cardíacos 
(Chakraborty et al. 2015; Cerro-Herreros et al. 2017). Se observó un aumento 
significativo de HP y AI en las moscas modelo, que imita el problema de 
conducción observado en pacientes con DM (Groh et al. 2008; McNally and 
Sparano 2011; Petri et al. 2012). Es importante destacar que ambos intervalos 
se vieron más afectados por las repeticiones de CCUG que por la expresión de 
repeticiones de CUG (Cerro-Herreros et al. 2017). Además, las moscas modelo 
tanto de DM1 como de DM2 mostraron una reducción de porcentaje de FS, que 
se correlaciona con una fracción de eyección ventricular disminuida observada 
en pacientes con DM (McNally and Sparano 2011; Hermans et al. 2012; Giovanni 
Meola and Cardani 2015). Curiosamente, en el tejido cardíaco, la expresión de 
repeticiones cortas produjo una prolongación leve pero significativa en el SI, 
que fue más pronunciada en el caso de las moscas que expresan CCUG 
(Chakraborty et al. 2015; Cerro-Herreros et al. 2017). La expresión de 20 
repeticiones de CUG / CCUG no indujo el secuestro de Muscleblind en foci. Por 
lo tanto, los fenotipos observados en estas moscas podrían ser independientes 
del secuestro de Muscleblind, y los factores que originan el fenotipo parecen 
ser más sensibles a la toxicidad por repeticiones CCUG. En ensayos de velocidad 
de escalada y de vuelo las moscas modelo se comportaron como los controles 
sugiriendo que la reducción en el porcentaje de FS de moscas que expresan 
C(C)TG no afectó a la demanda de carga de trabajo aguda (vuelo y escalada), 
pero sí tuvo un efecto acumulativo perjudicial sobre la supervivencia (Cerro- 
Herreros et al. 2017). 
2. Prueba de dos candidatos terapéuticos en el modelo de disfunción cardíaca 
DM1 de Drosophila: 
Durante mi trabajo, hemos estudiado los efectos de dos compuestos en los 
fenotipos cardiacos del modelo de DM1 en Drosophila que ya están 
publicados (Chakraborty et al. 2015 y Chakraborty et al. 2018). A continuación 
se explican a fondo. 
Moléculas pequeñas que inhiben la interacción Muscleblind-CUG tóxica 





de las moscas modelo como herramienta in vivo para buscar posibles 
compuestos terapéuticos contra la disfunción cardíaca en DM1 se verificó 
testando el efecto de un compuesto inhibidor de la interacción MBNL-CUGs ya 
conocido, la pentamidina. Posteriormente, usamos estas moscas modelo para 
testar el efecto anti-DM1 de una nueva molécula con potencial terapéutico la 
daunorubicina hidrocloruro. 
La pentamidina, que es un conocido compuesto anti-DM1, inhibe 
significativamente la interacción MBNL-CUG, reduce la formación de foci 
ribonucleares y libera MBNL de los foci en las células tratadas. In vivo, también 
se ha encontrado que la pentamidina rescata parcialmente los defectos de 
procesamiento alternativo de dos pre-mRNA en ratones que expresan CUGexp 
(Warf et al. 2009). Para probar el efecto de este compuesto en el fenotipo 
cardiaco de moscas modelo, se añadió pentamidina diluida en dimetilsulfóxido 
(DMSO) al medio nutritivo de las moscas hasta una concentración final de 1 μM 
(Chakraborty et al. 2015). Los parámetros moleculares y fisiológicos se 
compararon entre las moscas modelo alimentadas con pentamidina y las 
alimentadas solo con el solvente. En las moscas modelo tratadas con 
pentamidina, el rendimiento del corazón mejoró notablemente; se observó una 
reducción significativa en la arritmicidad (AI) y una recuperación importante de 
la contractilidad (% FS) en comparación con las moscas modelo tratadas solo 
con el solvente. Sin embargo, el SI y el DI afectados, que recuerdan a la 
disfunción sistólica y diastólica presente en pacientes, no fueron rescatados 
completamente por la pentamidina, aunque se observó una tendencia 
conspicua hacia los parámetros normales. Curiosamente, la mejora de los 
parámetros cardíacos fue suficiente para rescatar los valores medios de 
supervivencia de las moscas modelo tratadas con pentamidina. A nivel 
molecular, no se observaron diferencias significativas en el nivel de 
transcripción de las repeticiones en las moscas que tomaban pentamidina y las 
control. Además, hibridación in situ e inmunofluorescencia para detectar CUG 
RNA y Muscleblind, respectivamente, mostraron que los foci ribonucleares 
estaban ausentes en los núcleos de los cardiomiocitos y Muscleblind estaba 
disperso por todo el núcleo en las moscas modelo que tomaban pentamidina. 
En colaboración con el laboratorio del Dr. Charlet-Berguerand (IGBMC, INSERM, 





polarización de fluorescencia, descubrimos que el fármaco antitumoral, 
daunorubicina hidrocloruro, compite con MBNL por unirse a las repeticiones 
CUG in vitro (Chakraborty et al., 2018). La daunorubicina es un agente 
intercalante en presencia de dsRNA y dsRNA y se une competitivamente a las 
repeticiones de CUG e inhibe la unión de MBNL1 con una CI50 in vitro de 
alrededor de 100 nM. La técnica de fluorimetría de barrido diferencial (DSF) 
reveló que este compuesto estabiliza la estructura bicatenaria de las 
repeticiones de CUG in vitro y limita la accesibilidad de MBNL1 a las estructuras 
de ssRNA libres. La daunorubicina se probó en moscas en las mismas 
condiciones que la pentamidina. Este compuesto produjo una mejora notable 
en el rendimiento cardíaco de las moscas modelo (Chakraborty et al., 2018). A 
diferencia de la pentamidina, este compuesto mejoró todos los parámetros 
cardíacos, incluidos SI y DI. Es importante destacar que la mejora del 
rendimiento cardíaco también fue suficiente para recuperar los valores medios 
de supervivencia de las moscas que toman daunorubicina. A nivel molecular, 
este compuesto no modificó el nivel de expresión de las repeticiones. Además, 
la doble FISH/inmunofluorescencia mostró que los foci ribonucleares estaban 
ausentes en los núcleos de los cardiomiocitos y que Muscleblind se distribuyó 
por todo el núcleo en las moscas modelo que tomaban daunorubicina. Es 
importante destacar que esta liberación de Muscleblind mejoró 
significativamente el defecto de procesamiento de los transcritos Fhos y Serca 
en moscas modelo que tomaban daunorubicina (Chakraborty et al., 2018). 
Todos estos resultados apoyaban una mecanismo de acción de ambos 
compuestos basado en inhibir la interacción Muscleblind- RNA CUG, en lugar de 
en la inhibición de la transcripción. Esta liberación de Muscleblind podría ser la 
razón por la que los parámetros cardíacos y las alteraciones moleculares se 
recuperan en las moscas modelo. De hecho, el grado de recuperación fue 
diferente dependiendo del fármaco, p.ej la pentamidina no rescató 
completamente los intervalos sistólicos o diastólicos, pero la daunorubicina 
rescató ambos. Aunque es especulativo, es tentador sugerir que las diferencias 
en el grado de recuperación pueden originarse a partir de una mayor liberación 





3. Efecto de la sobreexpresión de Muscleblind en el modelo de disfunción 
cardíaca de DM1: 
Finalmente, en mi tercera publicación (Chakraborty et al., 2018) describí el 
efecto de la sobreexpresión de Muscleblind en fenotipos de corazón en 
moscas modelo DM1. 
Los resultados anteriores sugieren fuertemente que el secuestro de 
Muscleblind contribuye a la disfunción cardíaca. Para abordar específicamente 
esta cuestión, la isoforma C de Muscleblind [la isoforma mejor conservada 
evolutivamente] (Garcia-Casado, Artero and Perez-Alonso 2002) fue 
sobreexpresada junto con repeticiones CUG en cardiomiocitos de Drosophila. 
Como moscas control, en este caso se emplearon moscas modelo de DM1 que 
sobreexpresan GFP, tras haber demostrado que la expression del reportero GFP 
era inocua en el corazón y no alteraba los parámetros detectados en las moscas 
modelo. En contraste con la GFP, la expresión de MblC en moscas modelo 
corrige la disfunción cardiaca. Es importante destacar que el HP mejoró 
principalmente debido a una reducción del SI. La AI, el % FS y la contractilidad 
también se recuperaron significativamente en las moscas DM1 que 
sobreexpresaban Muscleblind. Todos los parámetros fueron recuperados 
excepto el intervalo diastólico que tal vez requiera una sobreexpresión más alta 
o la presencia de otras isoformas de proteína. Además, la recuperación del 
rendimiento cardíaco también mejoró la supervivencia media y vida máxima de 




































Discusión y perspectivas de futuro 




Discusión y perspectivas de futuro: 
 
Durante mi trabajo de tesis he generado y caracterizado, por primera vez en el 
campo de la distrofia miotónica, sendos modelos de disfunción cardiaca en 
Drosophila. En este trabajo se describieron los fenotipos cardiacos de moscas 
que expresan repeticiones C(C)UG largas y cortas. Los diferentes parámetros 
dinámicos del corazón, incluidos la frecuencia cardíaca, la ritmicidad, los 
intervalos sistólicos y diastólicos (SI y DI) y %FS se encontraron alterados en las 
moscas DM que expresaban expansiones largas en el corazón. La relevancia del 
modelo de DM está respaldada por las similitudes entre el fenotipo cardíaco de 
las moscas modelo de DM y las documentadas en individuos con DM (McNally 
and Sparano 2011). 
Es interesante destacar que SI y DI se vieron más afectados por las expansiones 
CCUG que por las CUG. De la misma forma, en el tejido cardíaco, la expresión 
de 20 repeticiones produjo una prolongación leve, pero significativa, en el 
intervalo sistólico, que fue más pronunciada en el caso de las moscas que 
expresan CCUG. Estas observaciones establecen paralelismos con ratones que 
sobreexpresan agudamente un número de repeticiones CTG dentro del rango 
normal en DMPK 3' UTR (5 repeticiones) y que reproducen características 
cardinales de la DM1, incluida la miotonía, anomalías de la conducción cardíaca, 
histopatología y defectos de empalme de RNA en ausencia de inclusiones 
nucleares detectables (Storbeck et al. 2004; M. S. Mahadevan et al. 2006). Los 
autores plantearon la hipótesis de que la sobreexpresión de DMPK 3 'UTR con 
un número pequeño de repeticiones podría comportarse como la expresión 
más débil de un RNA portador de expansiones largas generando fenotipos 
patológicos equivalentes. En las moscas modelo se observó un nivel de 
expresión similar tanto para los transgenes que expresan repeticiones cortas 
como largas, pero es posible que el grado de expresión sea suficientemente 
elevado como para generar fenotipos. Igual que en ratón, la expresión de 20 
repeticiones CTG no conduce a la formación de foci ribonucleares que retienen 
Muscleblind, pero es suficiente para inducir algunos fenotipos cardiacos. 
Los mecanismos patogénicos subyacentes a las diferencias fenotípicas entre 
DM1 y DM2 aún se desconocen. Varios estudios han confirmado que la 
frecuencia y la gravedad de la afectación cardíaca y de la debilidad muscular son 
más limitadas en DM2 en comparación con DM1 y la progresión es más lenta y 




menos grave en DM2. Esto sugiere que otras vías celulares y moleculares están 
involucradas además de la toxicidad al RNA C(C)UG, que es un mecanismo 
común. Se ha demostrado que tres factores influyen en el nivel de toxicidad de 
RNAs portadores de repeticiones expandidas: nivel de expresión, longitud, y 
secuencia. Asumiendo misma expresión, las secuencias más largas tienden a 
causar una patogénesis más grave pero, dependiendo de la secuencia, los 
factores de unión al RNA pueden verse afectados diferencialmente. Es 
importante destacar que, en pacientes con DM2, la gravedad de la enfermedad 
no se ha correlacionado directamente con el número de repeticiones, solo se 
ha establecido una relación entre tamaño de expansión y la tasa de secuestro 
de MBNL1. Los fenotipos similares en las moscas que expresan repeticiones 
CUG o CCUG expandidas sugieren la existencia de modificadores desconocidos 
en humanos, lo que podría mitigar la toxicidad del RNA en pacientes con DM2. 
Recientemente se ha demostrado que la proteína de unión a RNA rbFOX1 se 
une con expansiones CCUG. Esta proteína compite con MBNL1 por unirse a las 
repeticiones CCUG y libera MBNL1 de foci en células musculares DM2. 
Curiosamente, esta proteína no se une a las repeticiones CUG, lo cual explica 
bien la diferente presentación clínica de las dos enfermedades. De hecho, la 
sobreexpresión de rbFOX1 en Drosophila rescata la desregulación del splicing 
de transcritos musculares así como la atrofia muscular en un modelo en 
Drosophila (Sellier C et al. 2018). 
El rescate de los parámetros cardíacos utilizando pentamidina y daunorubicina 
respalda la especificidad del fenotipo de disfunción cardíaca y confirma el 
efecto deseable de ambos compuestos en un modelo in vivo. Ambos 
compuestos lograron una mejora a nivel fisiológico y molecular al rescatar 
diferentes parámetros cardíacos, disminuir la retención de Muscleblind en foci 
y corregir el procesamiento alternativo alterado de transcritos concretos. Es 
importante destacar que la pentamidina no restableció por completo todos los 
parámetros cardíacos. La función diastólica y sistólica se mantuvo alterada en 
las moscas tratadas. Por el contrario, la daunorubicina rescató completamente 
todos los parámetros cardíacos alterados en las moscas modelo DM1. 




Perspectivas de futuro: 
 
La extensa descripción y comparación que hemos realizado de los modelos de 
mosca de DM1 y DM2, permitirá el empleo de los mismos para el 
descubrimiento de modificadores genéticos que afecten diferencialmente a 
estas enfermedad pudiendo ser causantes de las diferencias clínicas entre los 
fenotipos de las mismas (ej. rbFOX), contribuyendo a aumentar el conocimiento 
sobre sus vías de patogénesis y hacia el desarrollo de nuevos tratamientos. 
Otro aspecto que todavía requiere mucha atención es la relevancia del 
secuestro de proteínas Muscleblind en la patología cardíaca. El trabajo con 
Drosophila indica claramente que la reducción de Muscleblind por secuestro 
contribuye a la patología, pero esto aún no se ha demostrado en modelos 
mamíferos. La transcriptómica del corazón de la mosca puede arrojar luz sobre 
este problema al descubrir los diferentes eventos moleculares que se alteran a 
consecuencia de dicho secuestro y cómo estas alteraciones pueden contribuir a 
los diferentes parámetros de disfunción cardíaca. 
Aunque Drosophila se comporta del modo esperado en cuanto a reproducir 
fenotipos de conducción cardiaca, desgraciadamente no se conocen bien los 
mecanismos subyacentes al origen del potencial del marcapasos en Drosophila 
lo que impide avanzar en la base celular y molecular de estas alteraciones. Otros 
estudios electrofisiológicos avanzados como p. ej. estudios de potenciales 
extracelulares e intracelulares y técnicas mecánicas como la microscopía de 
fuerza atómica (AFM) son necesarios para describir más de cerca el 
funcionamiento del corazón de la mosca normal y enferma. 
Respecto a la translacíon clínica de la daunorubicina, ésta debe tomarse con 
precaución debido a los efectos genotóxicos de este compuesto en 
tratamientos a largo plazo, por lo que se necesitarían estudios posteriores en 
modelos murinos de la enfermedad para determinar si podría considerarse un 
enfoque terapéutico adecuado para la DM1. En este sentido debe destacarse 
que los modelos aquí descritos permiten el testeo in vivo fácil y asequible de 
nuevas terapias experimentales en fenotipos cardiacos tales como el 
hexapeptido ABP1, previamente identificado por nuestro grupo (Garcia-Lopez 








































Las diferentes conclusiones que pueden extraerse de este trabajo son las 
siguientes: 
1. La expresión de repeticiones largas de CTG / CCTG en los corazones de 
Drosophila reproduce varios aspectos de la enfermedad humana tales como 
defectos de conducción, arritmias y defectos de contractilidad. 
2. A diferencia de lo que occure en humanos, el efecto de la sobreexpresión 
prolongada de CCUG en el corazón de la mosca fue muy similar al efecto de la 
expresión de repeticiones CUG . 
3. El RNA con repeticiones expandidas de C(C)UGs secuestra a Muscleblind en 
foci en núcleos de cardiomiocitos de Drosophila produciendo errores en el 
procesamiento alternativo de los transcritos de SERCA y Fhos en el corazón de 
la mosca. 
4. La sobreexpresión de Muscleblind es capaz de rescatar diferentes parámetros 
cardíacos a excepción de la disfunción diastólica. Por tanto, igual que en la 
musculatura esquelética, las expansiones C(C)TG provocan falta de función de 
Muscleblind también en tejido cardiaco. 
5. La expresión prolongada de repeticiones CUG o CCUGs en corazón produce 
desregulación de diferentes genes relacionado con la ruta de la autofagia. Estas 
alteraciones abren otro posible mecanismo de disfunción cardíaca en DM. 
6. Las moscas modelo de DM son una importante herramienta in vivo para 
probar diferentes terapias candidatas y llenar un vacío en los modelos animales 
disponibles. En este sentido la pentamidina, un conocido compuesto anti-DM1, 
ha rescatado los problemas cardíacos de DM1 y la daunorubicina, identificada 
en el marco de este trabajo, es un fármaco capaz de rescatar problemas 
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Pentamidine rescues contractility and rhythmicity in a Drosophila 
model of myotonic dystrophy heart dysfunction 
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Up to 80% of individuals with myotonic dystrophy type 1 (DM1) will 
develop cardiac abnormalities at some point during the progression of 
their disease, the most common of which is heart blockage of varying 
degrees. Such blockage is characterized by conduction defects and 
supraventricular and ventricular tachycardia, and carries a high risk of 
sudden cardiac death. Despite its importance, very few animal model 
studies have focused on the heart dysfunction in DM1. Here, we 
describe the characterization of the heart phenotype in a Drosophila 
model expressing pure expanded  CUG repeats under the control  
of the cardiomyocyte-specific driver GMH5-Gal4. Morphologically, 
expression of 250 CUG repeats caused abnormalities in the parallel 
alignment of the spiral myofibrils in dissected fly hearts, as revealed 
by phalloidin staining. Moreover, combined immunofluorescence 
and in situ hybridization of Muscleblind and CUG repeats, 
respectively, confirmed detectable ribonuclear foci and Muscleblind 
sequestration, characteristic features of DM1, exclusively in flies 
expressing the expanded CTG repeats. Similarly to what has been 
reported in humans with DM1, heart-specific expression of toxic RNA 
resulted in reduced survival, increased arrhythmia, altered diastolic and 
systolic function, reduced heart tube diameters and reduced 
contractility in the model flies. As a proof of concept that the fly heart 
model can be used for in vivo testing of promising therapeutic 
compounds, we fed flies with pentamidine, a compound previously 
described to improve DM1 phenotypes. Pentamidine not only released 
Muscleblind from the CUG RNA repeats and reduced ribonuclear 
formation in the Drosophila heart, but also rescued heart arrhythmicity 
and contractility, and improved fly survival in animals expressing 250 
CUG repeats. 






Myotonic dystrophy type 1 (DM1) is the most frequently inherited 
neuromuscular disease in adults. Aside from skeletal muscle 
symptoms, multi-organ involvement is also common and typically 
affects cardiac, endocrine and central nervous system tissues 
(Thornton, 2014). DM1 [Online Mendelian Inheritance of Man 
(OMIM) 160900] has been identified as an autosomal-dominant 
disorder  associated  with  the  presence  of  an  abnormal  CTG 
trinucleotide repeat expansion in the 3′ untranslated region (UTR) 
of the gene encoding myotonic dystrophy protein kinase (DMPK) 
on chromosome 19. Whereas 5-34 CTG repeats are observed in 
normal alleles, their number can reach up to between 50 and 2000 in 
DM1 (Brook et al., 1992; Fu et al., 1992; Mahadevan et al., 1992). 
The best-characterized effect of the expanded DMPK RNA 
(CUGexp RNA) is disruption of the function of RNA-binding 
proteins, including muscleblind-like 1 (MBNL1) and CUGBP 
Elav-like family member 1 (CELF1), which regulate multiple 
RNA-processing events, including alternative splicing, translation, 
polyadenylation, miRNAs biogenesis, mRNA stability and mRNA 
intracellular localization (Lee and Cooper, 2009; Batra et al., 2014; 
Meola et al., 2013; Rau et al., 2011; Adereth et al., 2005; Wang   
et al., 2012; Wang et al., 2015). CUGexp RNA impairs normal 
postnatal alternative-splicing transitions regulated by MBNL1 and 
CELF1. Whereas MBNL1 is sequestered to the CUG repeats, the 
toxic effect of mutant RNA on CELF1 activity is very complex, and 
involves increased CELF1 protein levels as a result of its 
stabilization in the nucleus (Kuyumcu-Martinez et al., 2007; Kim 
et al., 2014; Timchenko, 2013; Timchenko et al., 2001). As a result 
of disrupting the function of these proteins, several mis-splicing 
defects have been described and have been linked to specific 
symptoms of the disease (Mankodi et al., 2002; Savkur et al., 2001; 
Tang et al., 2012; Fugier et al., 2011). However, the physiological 
consequences of alternative splicing, gene expression and 
microRNA alterations in the heart are yet to be clarified (Phillips 
et al., 1999; Rau et al., 2011; Kalsotra et al., 2014; Zu et al., 2011; 
Lopez Castel et al., 2011; Moseley et al., 2006; Perbellini et al., 
2011; Fernandez-Costa et al., 2013; Wang et al., 2015). In general, 
cardiac involvement, which often precedes the skeletal muscle one, 
occurs in 80% of individuals with DM1 and represents the second 
most common cause of death of such individuals, after respiratory 
   failure (Vinereanu et al., 2004). Several studies have reported an 
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overall positive association between CTG-repeat size and cardiac 
involvement, and between the degree of neuromuscular and cardiac 
dysfunction (Petri et al., 2012; Groh et al., 2002; Dello Russo et al., 
2006). 
Three interrelated cardiac phenotypes are observed in individuals 
with DM1. The first is conduction defects, which are particularly 
common and can progress to complete heart blockage  (Nguyen  
et al., 1988). The second is the development of potentially fatal 
ventricular and/or atrial arrhythmias (Nigro et al., 2012; Benhayon 
et al., 2015). The third phenotype, although rarer, is mechanical 
diastolic and/or systolic dysfunction that can progress to combined 
systolic and diastolic heart failure (Phillips and Harper, 1997; 
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Cardiac involvement is a common complication of the skeletal muscle 
disorder myotonic dystrophy type 1 (DM1), occurring in 80% of DM1 
cases. Heart dysfunction is the second most common cause of fatality 
associated with the disease, after respiratory distress. DM1 is caused by 
the expansion of an unstable CTG repeat in the 3′ untranslated region 
(UTR) of the DMPK gene, which encodes myotonic dystrophy protein 
kinase. The expanded CUG repeats form a hairpin that sequesters the 
RNA-binding protein muscleblind-like 1 (MBNL1) and other nuclear 
factors into ribonuclear foci in a manner that is proportional to the CUG 
expansion size. Sequestration has been proposed to cause depletion of 
these proteins, leading to defects in splicing that underlie some of the 
clinical symptoms of DM1. Despite the central involvement of heart 
failure in DM1, very few studies have focused on the molecular cause of 
cardiac dysfunction in this disease and fewer have tested the effect of 




In this study, Beatriz Llamusi and colleagues generated and 
characterized a Drosophila model expressing pure expanded CUG 
repeats under the control of the cardiomyocyte-specific driver GMH5- 
Gal4. Supporting the suitability of this model to investigate cardiac 
dysfunction in DM1, the authors noted key similarities between the 
cardiac phenotype in DM1 model flies and those documented in 
individuals with DM1. First, they observed a reduction of median 
survival in model flies, which correlates to that reported in humans with 
DM1. Second, they observed a significantly increased heart period and 
arrhythmia index in the fly model, in line with heart conduction 
abnormalities that are common in DM1. Thirdly, they observed systolic 
and diastolic dysfunction reminiscent of that reported in affected 
humans. DM1 individuals with cardiac abnormalities generally show 
various extents of heart chamber dilation and hypertrophy, which result 
in decreased ventricular ejection. This phenotype was also mimicked in 
the fly model, which demonstrates reduced fractional shortening. 
Providing proof-of-concept, the authors also reported the efficacy of a 
known anti-DM1 compound, pentamidine, to partially rescue these heart 
phenotypes. Adult DM1 model flies fed with pentamidine showed 
reduced arrhythmicity and improved contractility, allowing a rescue of 
cardiac output that translated into a median survival that did not differ 
from control flies expressing 20× CUG repeats. However, the heart-rate 
dysfunction observed in the DM1 model flies was not completely rescued 
by pentamidine. 
 
Implications and future directions 
A better understanding of the molecular mechanisms altered by 
expansion of CTG repeats, and of the molecular interactions of the 
repeat sequence in vivo, is crucial for deciphering the origin of the 
symptoms of DM1 and to generate appropriate treatments. This work 
describes, for the first time, the toxic effects of long CUG RNA on cardiac 
function in a Drosophila model, paving the way for further studies to 
elucidate the molecular alterations underlying cardiac involvement in 
DM1. Moreover, the ability to detect changes in the phenotype in 
response to treatment with a known anti-DM1 compound confirms the 
specificity of the phenotype and its ability to respond to therapeutic 
intervention. Because several aspects of DM1 pathogenesis are still 
unclear, this model could be used to provide a more detailed description 
of heart involvement in DM1 and allow the identification of potential 
genetic modifiers of the heart alterations. Importantly, the model can also 
be used to test the efficacy of different therapeutic approaches that so far 
have only been tested in skeletal muscle. 
 
 
Mathieu et al., 1999; Lazarus et al., 2002; Groh et al., 2008).   
The majority of individuals with DM1 show abnormal 
electrocardiography (ECG) assessments, with prolonged time of 
conduction of the sinoatrial impulse to the ventricles (PR interval) 
(20-40% of affected individuals) and ventricular depolarization 
(QRS complex) widening (5-25%) (McNally and Sparano, 2011). 
Moreover, echocardiogram studies have also found that some 
individuals with DM1 have reduced heart contractility, as revealed 
by a lower left ventricular ejection fraction (LVEF less than 50%) 
(Dhand et al., 2013; Chaudhry and Frishman, 2012). 
Despite the relevance of heart involvement in DM1, the 
molecular mechanisms causing the abnormalities in electric 
conduction or contractility are not well understood. In previous 
inducible DM1 mouse models, conduction disturbances appeared 
a few days after inducing acute expression of either a short stretch 
of five CTG triplets or long interrupted CTG repeats (Wang et al., 
2007; Mahadevan et al., 2006). These studies pointed to 
alterations in cardiac conduction and excitability properties as an 
early event in the appearance of DM1-associated 
cardiomyopathies. Another mouse model was generated more 
recently that carries the human DM1 locus constitutively 
expressed under the regulation of its own promoter and its cis- 
regulatory elements (DMSXL). These mice constitute a good 
model of slow and steady-state expression of the triplet expansion, 
as is observed in individuals with DM1. However, cardiac 
abnormalities (reduced ventricular myocardium cell excitability) 
were not observed in baseline conditions; rather, they were only 
revealed after injection of the sodium-channel blocker flecainide 
(Algalarrondo et al., 2015). 
Adult Drosophila possess an open circulatory system consisting 
of a dorsal vessel, which is the 1-mm-long pulsatile heart tube, 
and an anterior aorta that extends through the thorax and into the 
head (for a review of Drosophila heart development and assessment 
see Ocorr et al., 2014). The simple structure and physiology of  
the Drosophila heart tube, together with its readily available 
genetics, provide a suitable in vivo assay system for studying cardiac 
dysfunctions. Here, we report the first Drosophila DM1 heart- 
dysfunction model, generated by overexpression of long pure CUG 
repeats {250 CUG repeats [CUG(250)×]} under the control of the 
cardiomyocyte-specific driver GMH5-Gal4. We have detected 
CUG ribonuclear foci and Muscleblind sequestration (the main 
molecular features of the disease in humans) in the Drosophila heart 
cell nuclei, and a shortened median survival and lifespan in DM1 
flies. We also measured several Drosophila heart parameters and 
found that these also resemble the heart dysfunction found in DM1 
humans. Importantly, we confirmed that oral administration of 
pentamidine to flies expressing long CUG repeats releases 
Muscleblind from these repeats and prevents foci formation in 
cardiac cell nuclei, also rescuing a subset of heart-dysfunction 
phenotypes. Our data suggest that Drosophila represents an 
appropriate DM1 heart-dysfunction model for physiopathological 
studies and supports the utility of this model for the heart-specific 
testing of potential therapeutic compounds. 
 
RESULTS 
Generation and characterization of a DM1 heart-dysfunction 
model in Drosophila 
To develop a heart-dysfunction model of DM1 in flies, we have 
generated UAS-CTG transgenic lines carrying 20 [CUG(20)×] or 
250 [CUG(250)×] pure CTG repeats and crossed them with the 
cardiac-specific driver GMH5-Gal4 (Wessells et al., 2004), which 
includes the UAS-GFP reporter, allowing the labeling of the tissues 
in which Gal4 is expressed. The level of expression of the repeats 
was assessed by qPCR analysis using primers against the common 
SV40 terminator (Fig. S1), and the transgenes were confirmed to 





























Hearts of flies expressing CUG repeats under the GMH5-Gal4 
driver were dissected for immunohistological and morphological 
assessment. Given the crucial involvement of Muscleblind protein 
in DM1 pathogenesis, it was highly relevant to confirm its 
expression in the Drosophila adult heart. Previous studies of 
Muscleblind expression in Drosophila have focused on adult 
skeletal muscle (Llamusi et al., 2013) or in the embryo (Artero et al., 
1998). In the current study, using an anti-Muscleblind antibody 
(Houseley et al., 2005), we observed Muscleblind expression in the 
adult heart cardiomyocytes. Muscleblind displayed a diffuse 
expression not only in the nucleus but also in the cytoplasm of 
cardiomyocytes, in both control (OrR) (not shown) and short- 
repeat-expressing flies (Fig. 1A-F). In contrast, Muscleblind was 
found concentrated in CUG ribonuclear foci in the nuclei in flies 
expressing long CUG expansions. Muscleblind sequestration is one 
of the main features of DM1. Ribonuclear foci were only present in 
the nuclei of heart cells in long-CUG-expressing flies (Fig. 1G-I). 
We also assessed the heart structure by staining actin, a structural 
component of the contractile machinery of muscles. Drosophila 
heart tubes have two types of muscle fibers, each with distinct 
 
Fig. 1. Characterization of the DM1 heart-dysfunction phenotype in flies. 
Representative fluorescent confocal images of adult heart cells from flies 
expressing short [CUG(20)×] or long [CUG(250)×] repeats under the control of 
GMH5-Gal4. (A-C) In cardiomyocytes expressing CUG(20)×, revealed by anti- 
GFP antibody (red, B), Muscleblind signal (green, A) was dispersed in the 
nuclei and cytoplasm. (D-I) Combined immunodetection of Muscleblind 
(green, D and G) and FISH to detect ribonuclear foci (red, E and H) revealed 
dispersed expression of Muscleblind and absence of foci in flies expressing 
short CUG repeats (D-F). However, in flies expressing long CUG 
repeats (G-I), Muscleblind colocalized with ribonuclear foci (arrows). 
(J,K) Representative confocal stacks of phalloidin (red)-stained spiral fibers in 
the region surrounding the ostia in adult hearts ( posterior A2-anterior A3 
segment) reveals details of the heart structure, in particular increased fiber 
disorganization in GMH5-Gal4›CUG(250)× flies. Arrowhead points to 
ostia-associated nuclei. Merged images in C,F,I,J and K include DAPI 
(blue) counterstaining of the nuclei. All images are from 7-day-old flies. 
Scale bars: 10 µm. 
myofibrillar structures (Mery et al., 2008; Taghli-Lamallem et al., 
2008): (1) spirally or transversely oriented myofibrils that represent 
the contractile ‘working’ myocardium; and (2) longitudinally 
oriented myofibrils that are found along the ventral surface of the 
tube (Molina and Cripps, 2001). In young flies, both types of 
myofibrils exhibit a tight and well-aligned arrangement. Cardiac 
myofibrils have been reported to stain uniformly along the entire 
length of the thin filament with phalloidin (Ao and Lehrer, 1995), 
so it can be used to visualize both types of myofibrils. 
Phalloidin staining of actin did not reveal gross structural 
abnormalities in the heart tube but found slight differences between 
flies expressing short or long CUG repeats in the areas surrounding 
the ostia. Cardiac myofibrils were tightly arranged and well aligned in 
short-repeat-expressing flies at 1 week of age. However, age-matched 
flies expressing long CUG repeats in heart showed abnormalities in 
the parallel alignment of transverse myofibrils, which showed a 
remarkable spiral disposition and less organized and compact 
arrangement of the myocardial myofibrils. These alterations have 
been also reported in aged fly hearts (Paternostro et al., 2001; 
Wessells et al., 2004; Taghli-Lamallem et al., 2008) (Fig. 1J-K). 
 
DM1 flies show a median survival reduction and 
arrhythmicity 
Population studies have reported higher mortality and morbidity 
rates, and a positive correlation between age at onset of DM1 and age 
at death in affected individuals (Breton and Mathieu, 2009). 
Similarly, we found that, as a result of long-CUG-repeat expression 
in heart, median survival and lifespan of flies were reduced at 29°C. 
The analysis of the survival curves showed that expression of long 
CUG repeats caused a significant reduction in the median survival of 
flies. From 47 days in control (GMH5-Gal4 UAS-GFP) and 41 days 
in short-repeat-expressing [GMH5-Gal4 UAS-CUG(20)×] flies, 
median survival was reduced to only 25 days in flies expressing 
long CUG repeats [GMH5-Gal UAS-CUG(250)×] (Fig. 2A). Of 
note, lifespan and median survival of short-repeat-expressing flies 
was not significantly reduced in comparison to controls (Fig. S3). 
To study heart function, adult fly hearts dissected in artificial 
hemolymph were recorded with a digital video camera. Because 
previous studies have reported that heart function changes with age, 
we selected 1-week-old flies for this study. Cardiac contractions 
were analyzed using a semi-automatic optical heartbeat analysis 
(SOHA) method to quantify the fly heart functional parameters. 
M-mode traces of movie clips provided details of the heart wall edge 
positions ( y-axis) over time (x-axis), illustrating the rhythmicity and 
the dynamics of the heart contractions (Ocorr et al., 2007). 
For the characterization of the cardiac phenotype of long-CUG- 
expressing flies, we compared their dynamic parameters with short- 
repeat-expressing flies to reveal the effect of the repeat length, and 
to two different controls: (1) F1 flies from crossing GMH5-Gal4 
and w− flies (abbreviated w−) to take into account potential 
contributions of the driver to the phenotype; and (2) F1 flies from 
crossing GMH5-Gal4 to UAS-GFP flies (abbreviated GFP), 
accounting for the dose of the UAS transgenes. 
The exposed and largely denervated heart in control and short- 
repeat-expressing flies showed rhythmic contractions; however, the 
contractions were clearly arrhythmic in hearts from flies expressing 
long repeats. We also observed morphological constrictions in 
small regions along the heart tube where no relaxation phase was 
observed (see Movie 1). Quantification of the heart period length 
(HP, defined as the diastolic plus systolic interval) showed that long- 
repeat-expressing flies exhibited a significantly increased HP 





























Fig. 2. Flies expressing long CUG repeats in Drosophila cardiomyocytes have a shortened median survival and increased arrhythmicity. (A) Average 
percentage of live flies, with the genotypes indicated, versus age (in days). Horizontal dotted line marks the median survival. Whereas control and short- 
repeat-expressing flies had a similar median survival of 47 and 40.5 days, respectively [GFP, n=40 and CTG(20)×, n=50], long-CUG-expressing flies lived a median 
of only 25 days [CTG(250)×, n=45). Differences in survival curves were highly significant (P<0.0001, log-rank test). (B,C) Heart period mean (HP, B), and arrhythmia 
index (AI, C) from flies expressing long and short CUG repeats and two types of control flies (F1 from crosses between the GMH5-Gal4 driver and w− or UAS-GFP). 
Both parameters are significantly increased in flies expressing long repeats. The bars on the graph show mean values and their standard errors. **P<0.01, 
***P<0.001, ns, not significant. (D-G) Representative M-modes (20 s) (D,F), with their respective histogram showing the percentage of beats and their duration 
(E,G), taken from movies of semi-intact fly hearts expressing long (D,E) or short (F,G) repeats. Red and blue horizontal lines represent the diastolic interval 
(DI) duration of CUG(250)×- and CUG(20)×-expressing flies, respectively. The systolic interval (SI) and the heart period (HP) length are also indicated in D. The HP 
histograms, plotted as individual data points (n=21, E; n=29, G), illustrate the variability of the HP within a group of flies expressing long (E) and short (G) repeats. 
 
The distribution of all of the measured HP for all flies of a specific 
genotype was represented in a histogram format, which revealed that 
the HPs clustered relatively tightly  in  the  short-repeat  flies,  
and that this distribution broadened in  long-CUG-expressing 
flies, emphasizing the increased variability in the HP (compare 
Fig. 2D,E and 2F,G). The variability in the heart periodicity can be 
quantified as an ‘arrhythmia index’ (AI) obtained by dividing the 
standard deviation of the HP by its median (Fig. 2C). Flies 
expressing long CUG repeats showed approximately a 50% increase 
in AI compared to control and short-repeat-expressing flies. 
 
Model flies display systolic and diastolic dysfunction, and 
reduced contractility 
Alterations of systolic and diastolic function, as well as decreased 
ventricular ejection fraction, have previously been reported in 
individuals with DM1 (Dello Russo et al., 2006). To test similar 
alterations in model flies, we measured the heart rate (HR), the 
diastolic and systolic intervals (DI and SI, respectively), and the 
end-diastolic and end-systolic diameters (EDD and ESD, 
respectively), and calculated the resulting percentage of fractional 
shortening (% FS), and compared them to control and short-repeat- 
expressing flies. We found that the increased mean HP, and the 
correspondingly reduced HR (HP=1/HR) observed in flies 
expressing  long  CUG  repeats,  were  caused  by  systolic  and 
diastolic dysfunction, because both SI and DI (contraction and 
relaxation period, respectively) were significantly prolonged in 
comparison to control and short-repeat-expressing flies. To note, the 
HP of CUG(20)× flies (Fig. 2B) was not significantly different to 
controls because the slight increment in SI observed was 
compensated by a decreased DI (Fig. 3B,C). Image analysis of 
heart contractions also provided cardiac chamber parameters, 
including EDD and ESD. In addition, the proportional decrease in 
heart wall diameter during contraction provides an indication of the 
cardiac output. Control flies displayed an average EDD of about 
70 μm and an ESD of 50 μm, and the average FS was higher than 
30%. In long-repeat-expressing flies, we observed a significant 
decrease in EDD (to 50 μm), and also a reduced FS of only 20% 
(Fig. 3D-F). These data revealed that heart tube volume is reduced 
and there is a dysfunction of the contractile properties in hearts 
expressing long CUG repeats. Interestingly, flies expressing short 
CUG repeats showed both reduced ESD and EDD but normal FS, 
suggesting that contractile dysfunction resulting in a reduced 
cardiac output was exclusive to long-repeat-expressing hearts. 
 
Pentamidine rescues  survival,  rhythmicity  and   contractility 
in                 the                 heart-dysfunction                  model 
To assess whether model flies could be used as an in vivo tool to search 





























Fig. 3. DM1 model flies displayed 
systolic and diastolic dysfunction, 
decreased diastolic diameter and 
contractility defects. Flies expressing 
long CUG repeats showed reduced heart 
rate [HR, A; expressed in beats per 
second (BPS)], increased diastolic (DI, B) 
and systolic (SI, C) intervals, reduced 
fractional shortening (FS, D), and 
decreased end diastolic diameter (EDD, 
E). The reduced contractility did not affect 
the end systolic diameter (ESD, F), which 
was not significantly different from 
controls. Short-repeat-expressing flies 
displayed an increased SI in comparison 
to control flies and had a reduced ESD 
and EDD, without any alteration of FS, 
suggesting that they have no contractility 
alteration. Graph bars show mean values 
and their standard errors (n used was 
between 14 and 29). *P<0.05, **P<0.01, 




DM1, we tested the effect of a known anti-DM1 compound on the 
Drosophila heart phenotype. Small molecules designed to inhibit the 
toxic MBNL1-CUG repeat interaction had shown relevant anti-DM1 
 
activity (Wong et al., 2014). Concretely, pentamidine significantly 
reduces the formation of ribonuclear foci, and releases MBNL1 from 




Fig. 4. Pentamidine rescued lifespan, median survival and arrhythmicity in DM1 model flies. (A) The average percentage of live flies, with the genotypes 
indicated, versus age (in days). Horizontal dotted line marks median survival. Model flies taking pentamidine [CUG(250)× P] had 40 days of median life, in 
comparison to only 28 days for long (CUG)250×-expressing flies fed with DMSO [CUG(250)× D]. The survival curves of model flies fed with pentamidine and 
control flies expressing short repeats fed with DMSO [CUG(20)× D] were not statistically different. (B) The heart period (HP) mean was not significantly altered by 
pentamidine administration, although a clear trend towards reduction was observed, whereas the arrhythmia index (AI) was strongly reduced (C). Graph bars 
show the mean values and their standard errors. *P<0.05, **P<0.01, ***P<0.001, ns, not significant. (D-G) Representative M-modes (20 s) (D,F) with their 
corresponding histograms (E, n=25; G, n=30) of percentage of beats of a given duration taken from movies of semi-intact flies expressing long repeats fed either 
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Fig. 5. Pentamidine improved 
contractility in model flies. Cardiac 
function parameters of short- and long- 
CUG-expressing flies fed either with 
DMSO [CUG(20)× D and CUG(250)× 
D] or pentamidine [CUG(250)× P], in 
comparison to controls. Pentamidine 
did not modify heart rate (HR, A), 
diastolic interval (DI, B), systolic interval 
(SI, C) nor end diastolic diameter (EDD, 
E) in model flies but strongly reduced 
end systolic diameter (ESD, F) in these 
flies, resulting in a relevant increase of 
fractional shortening (FS, D). Graph 
bars show the mean values and their 
standard errors (n used was between 
14 and 30). **P<0.01, ***P<0.001, 






partially rescue the splicing defects of two pre-mRNAs in mice 
expressing expanded CUG repeats (Warf et al., 2009). To test the 
effect of this compound in model flies, we added pentamidine diluted 
in dimethyl sulfoxide (DMSO) to the nutritive media to a final 
concentration of 1 µM. We tested the effect of DMSO in heart 
performance prior to these experiments and confirmed that, at the 
concentration used, it does not alter the cardiac parameters of 
Drosophila (Fig. S4). In comparison to model flies fed with DMSO, 
which have a median survival of 28 days, the median survival of 
model flies fed with pentamidine increased up to 40 days, which 
comes very close to the mean 47-day survival of control  flies  
(Fig. 4A). Moreover, there was a significant reduction in arrhythmicity 
(see Movies 1, 2 and Fig. 4C). Although in long-repeat-expressing 
flies fed with pentamidine [CUG(250)× P] mean HP was not 
significantly reduced (Fig. 4B), there was a clear reduction in the 
deviation of the HP values, which reflected in a more constrained and 
grouped HP histogram pattern in comparison to the long-CUG- 
expressing flies taking DMSO [CUG(250)× D] (compare Fig. 4D,E 
and F,G). The altered HR, SI and DI detected in the model flies, 
reminiscent of the systolic and diastolic dysfunction reported in 
affected humans, were not rescued by pentamidine, although we did 
observe a conspicuous trend towards normal parameters (Fig. 5A-C). 
An important recovery of heart contractile properties was observed in 
pentamidine-treated flies. We observed a decreased ESD and 
unchanged EDD, resulting into an increased FS (Fig. 5D-F). 
 
Pentamidine reduces foci and releases Muscleblind in 
cardiomyocytes of flies expressing long CUG repeats 
In order to address the mechanism of action of pentamidine, we 
performed fluorescence in situ hybridization (FISH) and 
immunofluorescence to detect foci and Muscleblind, in hearts of 
long-CUG-expressing flies that were fed 1 µM pentamidine. As 
previously reported in DM1 cells in culture (Warf et al., 2009), 
ribonuclear foci were absent in cardiomyocyte nuclei and 
Muscleblind was distributed throughout the nucleus (Fig. 6A-C). 
Moreover, because biochemical experiments and cell and mouse 
model studies suggest that pentamidine and related compounds 
might bind the CTG.CAG repeat DNA and inhibit transcription 
(Coonrod et al., 2013), we measured expression levels of CUGexp 
RNA in model flies fed with pentamidine or DMSO, detecting no 
significant  difference  (Fig.  6D).  These  data confirmed  that the 
rescue of the cardiac-dysfunction phenotype achieved by 
pentamidine was mediated by releasing Muscleblind sequestration 
rather than reducing toxic RNA expression level. 
 
DISCUSSION 
Here we described, for the first time, the characterization of the 
cardiac phenotypes of flies expressing either long or short CUG 
repeats as a DM1 heart-dysfunction model. We measured changes 
 
 
Fig. 6. Pentamidine mechanism of action. (A-C) Representative fluorescent 
confocal images of adult heart cells from long-CUG-expressing flies fed with 
pentamidine. Combined immunostaining of Muscleblind and CUG RNA FISH 
showed Muscleblind release (A) and no detectable foci (B) in the nucleus of 
cardiomyocytes of these flies. (C) Merge of A, B and DAPI; counterstaining of 
nuclei shows dispersed Mbl localization in nuclei. (D) Graph bar represents 
average fold changes of CUG(250)× expression in logarithmic scale, 
calculated by the 2−ΔΔCt method, and their confidence intervals. Pentamidine 
did not significantly alter expression level of CUG repeat RNA in model flies. ns, 
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in the heart dynamic parameters, including heart rate, rhythmicity, 
systolic and diastolic diameters and intervals (ESD, EDD, SI and 
DI), and FS. Moreover, we show that pentamidine, a compound 
with previously reported anti-DM1 activity, has the ability to 
modify the reported cardiac disease phenotypes. 
The relevance of the model is supported by the similarities between 
the cardiac phenotype in DM1 model flies and those documented in 
individuals with DM1. First, we observed a reduction in the median 
survival in model flies, which correlates with reports for affected 
humans (Petri et al., 2012). Cardiac mortality in individuals with 
DM1 usually occurs because of progressive left ventricular 
dysfunction, ischemic heart disease, pulmonary embolism, or as a 
result of unexpected sudden death (SD) associated with the corrected 
prolonged QT interval ( period including electrical depolarization and 
repolarization of the ventricles) (Park et al., 2013). Second, heart 
conduction abnormalities are common in individuals with DM1 
(Groh et al., 2008; McNally and Sparano, 2011). Similarly, we 
observed a significantly increased HP and arrhythmia index in our fly 
model. Although several arrhythmias have been reported in 
individuals with DM1, recent studies found that atrial fibrillation 
(AF) and atrial flutter (AFL) are frequent in DM1 and are linked to 
increased mortality (Brembilla-Perrot et al., 2014). Thirdly, the 
altered SI and DI observed in DM1 flies are reminiscent of systolic 
and diastolic dysfunction reported in humans with the disease 
(Penisson-Besnier et al., 2008; Hermans et al., 2012). Recently, 
echocardiography-Doppler found an increase of the mean left-atrial 
diameter and an increase of the mitral deceleration time in DM1 
individuals, suggesting diastolic abnormalities (Fayssoil et al., 2014). 
Left ventricular systolic dysfunction (LVSD) has also been reported 
in 7.2% of affected individuals (Petri et al., 2012). Moreover, 
individuals with DM1 with cardiac abnormalities generally show 
various extents of heart chamber dilation and hypertrophy, which 
results in a decreased ventricular ejection fraction (Dhand et al., 2013; 
Chaudhry and Frishman, 2012; McNally and Sparano, 2011; 
Pelargonio et al., 2002; Hermans et al., 2012) and correlates with 
the reduced FS we observed in model flies. 
We have also found cardiac defects in flies expressing short CUG 
repeats; mainly, slightly increased SI and reduced cardiac tube 
diameters. Interestingly, model mice acutely overexpressing a 
normal-length DMPK 3′ UTR mRNA reproduced cardinal 
features of myotonic dystrophy, including myotonia, cardiac 
conduction abnormalities, histopathology and RNA splicing 
defects in the absence of detectable nuclear inclusions (Storbeck 
et al., 2004; O’Cochlain et al., 2004; Mahadevan et al., 2006). 
Authors hypothesized that the effects of overexpressing many 
DMPK 3′ UTR transcripts with a small repeat number might be 
pathogenically equivalent to expressing mutant transcripts with 
hundreds of CUGs. In our flies, we measured a similar level of 
expression of the repeats in short- and long-expressing flies but used 
a potent promoter for overexpression (GMH5-Gal4). This driver 
includes a UAS-GAL4 element, allowing strong and continuous 
expression after induction. According to our data, controlled by this 
driver, expression of 20 CTG repeats does cause the formation of 
ribonuclear foci retaining Muscleblind but is enough to induce some 
cardiac phenotypes. Because MBNL loss in mice has been recently 
proven to be enough to cause cardiac pathology (Dixon et al., 2015), 
the finding of cardiac pathology in the absence of Muscleblind 
sequestration in our model flies becomes highly relevant because it 
shows a cardiac dysfunction mechanism that might be Muscleblind- 
independent in CUG-expressing flies. 
The rescue of the cardiac parameters using pentamidine supports 
the specificity of the heart-dysfunction phenotype and confirms the 
therapeutic effect of pentamidine in an in vivo model. Interestingly, 
pentamidine did not completely re-establish all cardiac parameters. 
Diastolic and systolic function remained altered, suggesting that 
either the effect of the pentamidine is limited, or the defect itself is 
not susceptible to therapeutic recovery in adults. This could be the 
case for alterations occurring early in development because the 
Drosophila heart is one of a few structures that persist during pupal 
morphogenesis, although it undergoes extensive remodeling (Rizki 
and Rizki, 1978). Similarly, in humans, CUG RNA toxicity during 
development could cause alterations in heart physiology or anatomy 
that cannot be modified by treatment in adults. This situation is not 
reproduced by inducible models expressing the CUG expansions 
after birth, only in models with constitutive CUG-repeat expression. 
Another heart-dysfunction feature that is not rescued by 
pentamidine is the reduced EDD found in the model flies. Of 
note, EDD was equally reduced in both flies expressing short and 
long repeats, suggesting that it might not require Muscleblind 
sequestration. Therefore, pentamidine might not be able to modify 
this parameter. Importantly, the rescue achieved by pentamidine 
was enough to increase FS, which correlates with hemolymph 
volume ejected, and corrected the heart arrhythmia, both of which 
are thought to be the most prevalent causes of sudden death in 
individuals with DM1. 
The long-repeat-expressing flies recapitulate many of the 
pathological and molecular features of DM1, including reduced 
survival, arrhythmias, systolic and diastolic dysfunction, and 
Muscleblind retention into ribonuclear foci. The rescue obtained 
by pentamidine treatment confirms that the DM1 model described 
has a sensitized phenotype that is suitable to unravel the mechanism 
of heart dysfunction in DM1 and to test potential therapeutic 
approaches in future studies. 
 
MATERIALS AND METHODS 
Drosophila strains 
Self-priming (CTG)20× and (CAG)20× synthetic oligonucleotides were 
cloned into the linearized pUAST vector to generate pUAST-CTG(20)×. 
PUAST-CTG(250)× was constructed by subcloning 500 uninterrupted CTG 
repeats from the pcDNA-CTG(500)× vector, which was a kind gift from Dr 
Partha Sarkar (Department of Neurology, University of Texas Medical 
Branch, TX). After cloning into pUAST and amplification into the STBL3 
(Invitrogen) Escherichia coli strain at 20°C, the 500 pure CTG repeats 
contracted to 250 CTG units. Transgenic flies carrying 250 or 20 pure 
repeats were generated by standard P-mediated transgenesis (BestGene Inc., 
Chino Hills, CA, USA). Transgenic lines carrying both long and short 
repeats were selected on the basis of moderate transgene expression and 
reproducibility of the phenotypes studied. In the fly lines used, the 
transgenes were located by inverse PCR to chromosome 2. The 
cardiomyocyte-specific driver GMH5-Gal4 (kindly provided by the 
laboratory of Dr Rolf Bodmer in the Burnham Institute, CA, USA) is a 
900 bp heart enhancer fragment 73 from the tinman gene that was cloned 
into the P{GaWB} vector upstream of the Gal4 sequences. This driver was 
enhanced with multiple copies of a UAS-Gal4 element allowing stronger 
myocardial expression and a UAS-GFP element allowing detection of the 
expression tissue (Wessells et al., 2004). All fly lines were maintained at 25° 
C with standard Drosophila food and standard day-night cycle. 
 
Quantification of CUG-repeat expression level 
Total RNA was extracted from ten flies per genotype using Trizol reagent 
(Sigma). DNase I treatment and reverse transcription were performed as 
previously reported (Llamusi et al., 2013). To quantify the expression of 
CUG RNA, the common SV40 terminator in the pUAST vector was used as 
target of the primers (F: 5′-GGAAAGTCCTTGGGGTCTTC-3′, R: 5′-G- 
GAACTGATGAATGGGAGCA-3′). Expression levels were normalized to 
the reference gene rp49 (F: 5′-ATGACCATCCGCCCAGCATAC-3′, R: 5′- 
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(Roche) under 2−ΔΔCt method. For each genotype, three biological samples 
were used and three technical replicates were performed. 
 
Detection of CUG-repeat length 
To confirm the length of the repeats in the UAS-CTG(20)× and UAS-CTG 
(250)× transgenes, 40 ng of genomic DNA was used as a template for the 
PCR amplification with KAPA HiFi (BIOSYSTEMS) and the primers: F 5′- 
GCAACTACTGAAATCTGCCAAGA-3′ and reverse- 5′-GTTGAGAGT- 
CAGCAGTAGCC-3′, which flank the repeats. The region amplified by the 
primers includes the short repeats (60 bp) and 375 bp of the CTG(20×) 
plasmid, and the long repeats (750 bp) and 428 bp of the CTG(250)× 
plasmid. PCR amplification was performed under the following conditions: 
95°C for 2 min, followed by 30 cycles of 98°C for 20 s, 65°C for 30 s, 72°C 
for 1 min and final extension at 72°C for 5 min. The PCR products were 
analyzed by electrophoresis at 110 V in 1.5% agarose gels. 
 
Pentamidine                                                           treatment 
Pentamidine was added to the standard food to a final concentration of 1 µM 
in 0.1% DMSO (Applichem). The control group of flies was fed with 0.1% 
DMSO. Flies were transferred every 3 days to new fresh food media, with or 
without pentamidine for the duration of their whole lifespan in life survival 
experiments or every 7 days in the case of the group used for cardiac 
analysis. 
 
Survival                                                                                 analyses 
For survival analyses, a minimum of 40 female flies from the corresponding 
genotypes were collected and kept at 29°C. Flies were transferred to new 
fresh nutritive media every second day and scored for deaths daily. 
Statistical analysis was performed with a log-rank test using the GraphPad 
Prism5 software. 
 
Cardiac                               physiological                               analysis 
For the physiological analysis, female flies were collected just after eclosion 
and were maintained for 7 days at 29°C. For the heart beat recordings, semi- 
intact heart preparations were made as previously described (Ocorr et al., 
2007; Magny et al., 2013). An inverted Leica DM Irbe microscope, 
connected to a DFC450C Leica digital camera, was used to take 20 s 
recordings at 29 frames/s. Different cardiac parameters were measured using 
Fly_heart_analysis (SOHA) software based on Matlab R2009b 
(MathWorks, Natick, MA, USA) (Ocorr et al., 2007). For the statistical 
analysis, Student’s t-test was used with Welch’s correction when the 
variances were different. 
 
Fluorescent immunofluorescence analysis 
Fly hearts were dissected from 7-day-old females, fixed for 20 min in 4% 
paraformaldehyde, and washed in PBT (PBS containing 0.3% Triton X-100). 
Muscleblind staining and FISH to detect ribonuclear foci were performed as 
previously described (Llamusi et al., 2013). For double Muscleblind and 
GFP staining, dissected hearts were washed in PBT and incubated in 
blocking buffer (PBS containing 0.3% Triton X-100, 5% donkey serum and 
0.5% bovine serum albumin) for 30 min prior to overnight incubation at 4°C 
with primary antibodies sheep-anti-Muscleblind (Houseley et al., 2005) and 
rabbit anti-GFP (#G10362, Invitrogen) diluted 1/500 in blocking buffer. 
After several PBT washes, the tissue was incubated for 45 min with biotin- 
conjugated secondary antibodies (#31840, Thermoscientific) at 1:200 
dilution and then incubated with ABC solution (ABC kit, VECTASTAIN) 
for 30 min at room temperature, followed by washes and 45 min incubation 
with anti-rabbit FITC (#F9887-5ML, Sigma) secondary antibody and 
streptavidin–Texas-red (1:1000, #SA5006, VECTOR). For phalloidin 
staining, phalloidin (#P1951, Sigma) was diluted 1:1000 in PBT and 
tissues were incubated for 20 min. Samples were mounted in Vectashield 
(Vector) as described before (Alayari et al., 2009). All confocal images were 
taken in an Olympus FV1000 microscope. 
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Expanded CCUG repeat RNA 
expression in Drosophila heart and 
muscle trigger Myotonic Dystrophy 
type 1-like phenotypes and activate 
autophagocytosis genes 
Estefania Cerro-Herreros1,2,3, Mouli Chakraborty1,2,3, Manuel Pérez-Alonso1,2,3, 
Rubén Artero 1,2,3 & Beatriz Llamusí1,2,3 
Myotonic dystrophies (DM1–2) are neuromuscular genetic disorders caused by the pathological 
expansion of untranslated microsatellites. DM1 and DM2, are caused by expanded CTG repeats in the 
3′UTR of the DMPK gene and CCTG repeats in the first intron of the CNBP gene, respectively. Mutant 
RNAs containing expanded repeats are retained in the cell nucleus, where they sequester nuclear 
factors and cause alterations in RNA metabolism. However, for unknown reasons, DM1 is more severe 
than DM2. To study the differences and similarities in the pathogenesis of DM1 and DM2, we generated 
model flies by expressing pure expanded CUG ([250]×) or CCUG ([1100]×) repeats, respectively, and 
compared them with control flies expressing either 20 repeat units or GFP. We observed surprisingly 
severe muscle reduction and cardiac dysfunction in CCUG-expressing model flies. The muscle and 
cardiac tissue of both DM1 and DM2 model flies showed DM1-like phenotypes including overexpression 
of autophagy-related genes, RNA mis-splicing and repeat RNA aggregation in ribonuclear foci along 
with the Muscleblind protein. These data reveal, for the first time, that expanded non-coding CCUG 
repeat-RNA has similar in vivo toxicity potential as expanded CUG RNA in muscle and heart tissues and 
suggests that specific, as yet unknown factors, quench CCUG-repeat toxicity in DM2 patients. 
 
 
Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are dominantly-inherited multi-systemic genetic disorders. 
DM1 (OMIM: 160900) is caused by an unstable expansion of a CTG trinucleotide repeat motif located in the 3′ 
untranslated region (UTR) of the dystrophia myotonica protein kinase (DMPK) gene1. Unaffected individuals 
carry fewer than 37 triplet-repeats, whereas expansions ranging between 50 and 4000 CTG repeats have been 
found in affected individuals. DM2 (OMIM: 602668), initially named proximal myotonic myopathy due to the 
greater weakness of proximal compared to distal muscles2, is caused by a tetranucleotide (CCTG) expansion in 
intron 1 of the CCHC-type zinc finger nucleic acid binding protein gene (CNBP, also known as ZNF9)3. Healthy 
individuals carry fewer than 30 tetra-nucleotide repeats, whereas repeat lengths found in affected patients are 
significantly longer than in DM1 (between 55 and 11000)3. In contrast to DM2, which does not have a congen- 
ital form, very large (>1,000 repeat) DMPK CTG mutations also cause congenital DM1 (CDM) characterized 
by neonatal hypotonia (floppy baby) and intellectual disability4. The expansions are transcribed into (CUG)n 
and (CCUG)n-containing RNA, respectively, which form secondary structures and sequester RNA-binding pro- 
teins, such as the RNA processing factors Muscleblind-like proteins (MBNL1-3 in vertebrates, Muscleblind in 
Drosophila), forming nuclear aggregates known as foci5–11. Additional splicing factors, such as CUGBP Elav-like 
family member 1 (CELF1), are also disrupted, leading to the mis-splicing of a large number of downstream 
genes12–14. Among them, the alteration in the splicing pattern of CLCN1, INR, PKM, CACNA1S, and BIN1 
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pre-mRNAs has been associated with myotonia, insulin resistance, perturbed glucose metabolism and muscle 
weakness, respectively, which are all symptoms of DM15–19. Importantly, the repeat-length extensively correlated 
with disease severity in DM120 and with the amount of MBNL sequestered in both types of DM5, 21. Although 
for DM2 the correlation between repeat length and disease severity in humans is less clear-cut, expression of 
non-coding CCUG-expanded RNA in flies has been shown to cause length-dependent toxicity in Drosophila 
eyes22. 
Clinically, DM2 patients generally experience a milder phenotype than DM1 patients, including slower and 
less severe progression of the disease, reduced severity of the cardiac involvement with a significant reduction in 
arrhythmicity and prophylactic pacing requirements, lack of prominent late respiratory or facial and bulbar mus- 
cle weakness, less evocable myotonia, and preserved social and cognitive abilities23–26. However, the molecular 
origin of these milder phenotypes in DM2 is unknown. Indeed, several studies have reported that DM2 individ- 
uals tend to carry significantly more (75 to approximately 11,000, with a mean of 5,000 CCTG) repeats in mutant 
alleles compared to patients with CTG expansions (classic DM1 range is 100–1000 repeats)3 and, according to 
different sources CNBP is 4 to 8-fold more expressed in human muscles than the DMPK gene27–29. In addition, 
MBNL binds to CCUG with higher affinity than to CUG repeats6, 30, resulting in larger ribonuclear inclusions in 
DM2 patients, which sequester more MBNL21. Considering that CNBP is expressed at higher levels than DMPK 
in muscles, and that expanded alleles tend to carry more CTG repeats, as well as the fact that MBNL proteins have 
higher affinity for CCUG repeats than for CUG RNA, DM2 symptoms should be more severe, rather than milder, 
than DM1. 
To investigate this paradox, we reasoned that the phenotypes brought about by both expansion types in 
Drosophila tissues might be informative. Significantly, weaker phenotypes are expected for CCUG expansions 
should they be intrinsically less toxic than CUG repeats, whereas similar phenotypes are expected if toxicity  
is modulated in humans by CCUG-specific factors. With this aim, we generated and characterized Drosophila 
models of DM1 and DM2 expressing pure CUG or CCUG repeats, respectively, in muscular and cardiac tissues. 
We found common pathogenic events between CUG and CCUG repeat toxicity, such as Mbl sequestration in foci, 
mis-splicing and increased autophagy in both tissues. Importantly, the severity of the phenotypes in the DM2 
flies reveals that CCUG repeat expansions are potentially as toxic as CUG repeats in muscle and heart. Our study 
therefore suggests that unknown molecular RNA-toxicity modifiers account for the milder symptoms of DM2. 
Results 
Expression of either CUG or CCUG-expanded repeats sequester Muscleblind in ribonuclear foci 
in muscle and cardiac tissue. To accurately model DM1 and DM2 in flies, we generated UAS-CTG and 
UAS-CCTG transgenic fly lines carrying either 250 CTG (CTG (250)×) or 1100 CCTG (CCTG (1100)×) pure 
repeats, which are within the pathological range of repeat lengths and mimic the, at least 4 times longer, expan- 
sion size in DM2 patients compared with DM125, 31. As controls, we generated flies carrying short versions of the 
repeats (CTG (20)× or CCTG (20)×). In order to express the repeats in different tissues, we crossed the UAS fly 
lines with the muscle-specific driver myosin heavy chain Mhc-Gal432 or the cardiac-specific driver GMH5–Gal433. 
The expression level of the repeats was assessed by qPCR using primers against the common SV40 terminator 
contained in these vectors (Fig. S1). 
Fluorescent in-situ hybridization (FISH) to detect ribonuclear foci showed that they were present in the nuclei 
of indirect flight muscle (IFM) and heart cells expressing long CUG or CCUG repeats, but not in flies expressing 
the short versions of the repeats (Figs 1 and S2). Because Muscleblind sequestration is one of the main features 
of the disease, we studied Muscleblind subcellular localization in our model flies. As we previously reported, 
Drosophila Muscleblind is found in sarcomeric bands in adult muscle tissue and dispersed throughout the nuclei 
of cardiomyocytes34, 35. Muscleblind immunodetection in muscle and heart tissue in flies expressing the short 
versions of the CUG or CCUG repeats showed that Muscleblind localization was the same as that described in 
control samples. In contrast, Muscleblind was concentrated in CUG or CCUG ribonuclear foci in muscle and 
heart cells from flies expressing long CUG or CCUG repeats (Fig. 1). Thus, both expanded CUG and CCUG 
arrays originate ribonuclear foci and Muscleblind sequestration in Drosophila muscle and heart tissue, which are 
both histological hallmarks of DM. 
 
Muscleblind-dependent splicing is altered in flies expressing expanded CUG or CCUG 
repeats. To test whether the confirmed Muscleblind retention in foci was enough to cause splicing mis- 
regulation, we studied the percentage of exon retention (“percentage spliced in”, PSI) of the Drosophila formin 
(Fhos) gene exon 16′, which has a highly conserved ortholog in human, with altered splicing in DM1 patients36. 
Fhos has 19 exons, which produce nine different transcripts (Ensembl Genome browser, release 83). We recently 
reported that exon 16′ (132 nt) is preferentially included in DM1 model flies expressing 480 interrupted CUG 
repeats (i(CUG)480) in muscle37. Importantly, this splicing event was shown to be Muscleblind-dependent. In 
control flies, the PSI of Fhos exon 16′ was around 50%. However, in flies expressing i(CUG)480 in muscle, this 
percentage increased to nearly 95%. Consistent with the milder toxic effects reported in DM1 individuals and 
in animal models with shorter CUG repeats, the inclusion percentage dropped to close 75% in flies expressing 
250 CUG repeats in muscle. In the case of flies expressing expanded CCUG repeats in muscle, we also observed 
increased Fhos exon 16′ inclusion, which reached 85%. Importantly, flies expressing short versions of either 
CUG or CCUG repeats, showed no significant changes in exon usage (Fig. 2A and C). In cardiac tissue, the 50% 
exon inclusion found in control or short-repeat-expressing flies, increased to 75% in both expanded CUG and 
CCUG-expressing flies (Fig. 2B and D). We also quantified the inclusion of exon 13 of the Mbl-dependent Serca 
gene, which decreased 50% in the flies expressing the long repeats in muscle, while in heart, resulted into a 50% 
increase. Accordingly, in previous studies the expression of 480 interrupted CUG repeats in adult flies using the 








Figure 1. Muscleblind is retained in ribonuclear foci in flies expressing expanded CUG or CCUG repeats. 
Representative fluorescent confocal images of IFMs (A–F) and heart cells (G–L) from flies expressing expanded 
CUG (A–C and G–I) or CCUG (D–F and J–L) repeats under the control of the Mhc-Gal4 and GMH5-Gal 
drivers, respectively. Ribonuclear foci retaining Muscleblind were present in flies expressing long CUG or 
CCUG repeats. Merged images in (C,F,I and L) include DAPI (blue) counterstaining of the nuclei. Scale 
bar = 10 µm. 
 
 
late muscle driver Mhc-Gal4 induced a 2.4-fold reduction of Serca transcripts with exon 1337, while the expres- 
sion of 960 CUG repeats using the Mef-Gal4 driver resulted in increased expression38, suggesting a remarkable 
developmental-dependent regulation of this event in flies (Fig. 2E and F). 
These data confirmed that the Muscleblind sequestration in ribonuclear foci observed in fly models of DM1 
and DM2, led to a functional depletion of Muscleblind in adult muscle and heart tissue. 








Figure 2. CUG and CCUG expansions cause Muscleblind-dependent missplicing. (A,B) Representative semi- 
quantitative RT-PCR showing inclusion of Fhos exon 16′ in flies expressing the indicated constructs in muscle 
(A) or heart (B) under the control of Mhc-Gal4 or GMH5-Gal4, respectively. Endogenous Rp49 was used for 
normalization. Percentage of exon 16′ inclusion, revealed that expression of long CUG or CCUG repeats in the 
fly muscle (C) or heart (D), favored increased use of this exon. qRT-PCR results of Serca exon 13 expression 
relative to Rp49 expression, confirmed that the use of this exon in the flies expressing the expanded repeats 
and the control flies is significantly different in muscle (E) and heart tissues (F). The histograms show the 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t-test). 
 
 
The expression of autophagy-related genes is increased in muscular and  cardiac tissues 
in DM1 and DM2 model flies. Several studies have reported a pathological over-activation of the 
autophagy-lysosome pathway in DM1 models. Apoptotic activation and increased presence of autophagy markers 
has been reported in primary human cell lines from adult-onset DM1 patients39, 40 and in human DM1 embryonic 
stem cells-derived neural stem cells41. In addition, pathway analysis on global PolyA-seq studies of human DM 
skeletal muscle42 and brain43 identified enriched terms associated with ubiquitin-mediated proteolysis and the 
mTOR pathway. More recently, studies performed in a murine model of DM1 have reported that targeting dereg- 
ulated AMPK/mTORC1 pathways improves muscle function in DM144. Accordingly, we have previously demon- 
strated over-activation of apoptosis and autophagy by inducible expression of 480 interrupted CUG repeats in 
Drosophila adults and a rescue of muscle atrophy by silencing the expression of the autophagy-related genes Atg4, 
Atg7, Atg8a and Atg934. To study the expression of autophagy-related genes in our DM1 and DM2 Drosophila 
models, we performed qPCRs with cDNAs from heart and thorax samples of flies expressing short and long 
versions of the CUG or CCUG repeats in heart and muscle (Fig. 3). In general, we found that expression of Atg4, 








Figure 3. The expression of autophagy-related genes is upregulated in flies expressing expanded CUG or 
CCUG repeats in muscle or heart. Relative expression levels of Atg4, Atg7, Atg8a, Atg9 and Atg12 measured by 
qRT-PCR in muscle (Mhc-Gal4 driver; A) and heart samples (GMH5-Gal4 driver; B), showed a significant 
upregulation of these autophagy-related genes in flies expressing expanded CUG (CUG(250)×) or CCUG 




Atg7, Atg8a, Atg9 and Atg12 were significantly upregulated in flies expressing either expanded CUG or CCUG 
repeats in muscle, compared to control flies expressing GFP or short repeats. Of note, the expression levels of 
these genes in flies expressing short CUG or CCUG repeats were similar to the levels in control flies that did not 
express the repeats (Fig. 3A). In comparison, the expression of the repeats in heart caused a moderate upregula- 
tion of Atg genes expression, in the case of flies expressing the long repeats. Upregulation of Atg genes mediated 
by the repeats was higher in the flies expressing CCUGs compared to those expressing CUG repeats (Fig. 3B). 
Consistent with these findings, we observed upregulation of AKT2, AKT1S1 and ATG4 mRNAs in human patient 
skeletal muscle34. These data support a role of autophagy activation in DM pathogenesis not only in DM1, as we 
previously reported, but also in DM2. In addition, our results highlight the relevance of the activation of this 
pathway in different tissues affected by repeat expression. 
 
Both expanded CUG and CCUG repeat RNA reduced cross-sectional muscle area and fly sur- 
vival. Despite the fact that MBNL1 is sequestered in CCUG foci and it is expected that the longer CCUG 
repeat expansions will have a greater inhibitory effect on MBNL1 in DM2 cells, visible muscle atrophy in DM2 
muscle is actually milder than in DM1 patients45. To investigate how Drosophila muscle responds to expanded 
CCUG repeat RNA, we quantified the cross-sectional muscle area of IFMs from adult flies at different ages that 
expressed 250 CUG or 1100 CCUG repeats, or controls expressing 20 units or the GFP reporter, under the con- 
trol of the Mhc-Gal4 driver. We observed a significant reduction in muscle area in 3-day-old flies expressing long 
CUG or CCUG repeat RNA, whereas cross-sectional muscle area in flies expressing the short versions of the 
repeats were not significantly different from control GFP-expressing flies. Importantly, flies expressing either long 
CUG or CCUG repeats showed similar muscle phenotype, which reached up to a 50% reduction in muscle area in 
both cases (Fig. 4A–E and K). Similarly, muscle area in aged flies (30-day-old flies) expressing expanded repeats 
was reduced in comparison to aged GFP flies. The decrease in the muscle area in young and aged flies was similar 
in all the genotypes studied (around 20%) suggesting that the strong muscle reduction observed in the model flies 
had an important developmental component. Nevertheless, we observed vacuolization, splitting muscles and 
occasional absence of muscle packages, characteristic of degenerating muscles46, which were only present in aged 
flies expressing the expanded CUG or CCUG repeats (Fig. 4F–K). Taken together, these results suggests that toxic 
RNAs interfere with both muscle development and muscle maintenance. 
Population studies have reported higher mortality and morbidity rates, and a positive correlation between the 
age at onset of DM1 and age at death in patients47, 48. Similarly, we observed that the lifespan and mean survival 
of flies expressing expanded CUG or CCUG repeat RNA was significantly reduced in comparison to control flies 
expressing only GFP, whereas the lifespan of flies expressing 20 units of the repeats was not significantly different 
from the control flies (Fig. 5A). These results are consistent with our previous description of muscle loss, degen- 
eration and reduced viability of flies expressing i(CTG)480 throughout the fly musculature34, 49. Taken together 
our data indicate that the expression of expanded CUG or CCUG repeats in muscle causes similar defects in the 
IFMs of young and aged flies, and in the viability of Drosophila. 
 
Locomotor performance is compromised in flies expressing expanded CUG or CCUG repeat 
RNA in muscle. To test whether the muscle loss observed in the model flies was of functional relevance, we 
assessed the flight and climbing ability of flies expressing the expanded repeats and compared them to control 
flies expressing GFP or short repeats. Climbing velocity and landing distance were only reduced in flies express- 
ing the expanded versions of the repeats and no significant differences were observed between DM1 and DM2 
model flies. Of note, these functional parameters were not altered in flies expressing the short versions of the 
repeats compared to the controls. In the case of climbing velocity, flies expressing the long CUG or CCUG repeats 
retained 70% of the control-fly climbing speed, and there was no significant difference in velocity between these 
two genotypes (Fig. 5B). The average landing height was reduced to 25% compared to control flies expressing 








Figure 4. Expression of expanded CUG or CCUG repeats in muscle induces similar levels of muscle area 
reduction and degeneration. (A–J) Dorsoventral sections of resin-embedded fly thoraces. In all images the 
dorsal side is displayed at the top. Mhc-Gal4 was used to drive the expression of the indicated constructs in 
muscle. (K) Quantification of the mean percentage of muscle area per genotype relative to the muscle area of the 
control flies (GFP), which is considered as 100%. While young flies (3 day-old, in A–E) expressing 20 CUG or 
CCUG repeats were not different from control flies expressing GFP, flies expressing expanded CUG or CCUG 
repeats have a 50% reduction in IFM muscle area. All aged flies (30 day-old, in F–J) displayed reduced muscle 
area compared to young flies of the same genotype. However, vacuolization (arrows) and occasional muscle 
splitting (asterisk) characteristic of degenerating muscles were present only in muscles expressing expanded 
repeats. The graph shows the means ± SEM. *p< 0.05, **p< 0.01, ***p< 0.001 (Student’s t-test). 
 
 
GFP or 20 units of the repeats, and was similar in flies expressing either expanded CUG or CCUG repeat RNA 
(Fig. 5C). Thus, in contrast to human patients, where DM2 muscle disability is milder than in DM1, these data 
indicate that expression of long CUG or CCUG repeat RNA in muscle tissue has a similar effect on locomotion 
in flies. 
 
Heart dysfunction in both DM1 and DM2 model flies includes systolic and diastolic alterations, 
arrhythmia, and contractility defects. Cardiac alterations, characterized by conduction delays, arrhyth- 
mia, and heart blockage are the second most common cause of death in DMs50. In DM2, cardiac abnormalities 
have been reported to be similar to those described in DM1 but less frequent and severe24. To study heart func- 
tion in the Drosophila DM models, adult fly hearts were dissected in artificial hemolymph and recorded with a 
high-speed video camera. Cardiac contractions were analyzed using a semi-automatic optical heartbeat analysis 
(SOHA) method to quantify the fly heart functional parameters51. The study of heart function in DM2 model 
flies revealed that expression of long CCUG repeats in fly heart caused lengthening of the heart period (HP), 
and extension of the systolic and diastolic intervals (SI and DI, respectively). Heart contraction, measured as a 
percentage of fractional shortening (%FS), and arrhythmicity measured using the arrhythmia index (AI), were 








Figure 5. Survival and locomotor function were reduced in flies expressing expanded CUG or CCUG repeats 
in muscle. (A) Average percentage of live flies versus age (in days). The Mhc-Gal4 driver was used to induce 
the expression of the indicated constructs in muscle. The horizontal dotted line marks the median survival. 
Whereas control and short-repeat-expressing flies had similar median survival (GFP; n= 90, CUG(20)×, 
n= 100 and CCUG(20)×, n= 95), long CUG and CCUG-expressing flies have reduced survival (CUG(250)×; 
n= 95 and CCUG(1100)×; n= 100). Differences in the survival curves were highly significant (p< 0.0001, log- 
rank test). (B) Histogram showing the climbing speed as the mean speed± SEM in mm/s. Flies expressing long 
CUG or CCUG repeats had reduced climbing velocity compared to control flies or flies expressing the short 
versions of repeats. (C) Notched box plot showing the median and the distribution of the average landing height 
data obtained in the flight assay with the relevant genotypes. Flight disability was observed in flies expressing 
long CUG or CCUG repeats. *p< 0.05, **p< 0.01, ***p< 0.001 (Student’s t-test). 
 
 
significantly altered compared to controls. In these model flies, the %FS was reduced to 20% and AI increased 
by around 3-fold (Fig. 6D,E). Importantly, the expression of short CCUG repeats did not affect %FS or AI but 
it increased the SI compared to controls, and resulted in a significantly increased HP (Fig. 6A–C). Similarly, we 
previously reported, that overexpression of expanded CUG repeats in Drosophila heart results in an increased HP 
with prolonged DI and SI, a reduction in %FS, and increased AI. In contrast, the expression of short CUG repeats 
only produced a slight increase in the SI duration35. 
 
Expression of expanded CUG or CCUG repeat RNA in fly heart reduces survival but does not 
affect locomotion. We previously reported that overexpression of long CUG repeats in fly heart results in a 
reduction in mean survival and lifespan35. The mean survival in control flies expressing GFP was 29 days which 
was reduced to about half in the DM1 model flies. The survival curve for flies expressing CCUG repeats in heart 
tissue was also significantly reduced compared to the GFP control flies. Of note, the survival curve of flies express- 
ing short CUG or CCUG repeats was similar to that of control flies (Fig. 7A). These data suggest that the cardiac 
alterations in our DM1 and DM2 models affect the survival of flies. 
To assess whether the expression of repeats in heart affects locomotor performance in flies, we analyzed the 
climbing velocity and landing distance of flies expressing CUG or CCUG repeats and found that neither the 
expression of short nor long versions of CUG or CCUG repeats affected these abilities (Fig. 7B,C). Thus, the 
reduction in %FS did not affect acute workload demands (flight, and climbing), but did have an accumulative 
detrimental effect on survival. 
Materials and Methods 
Drosophila strains. Pure expanded CTG and CCTG repeats were generated by PCR amplification of self-
priming single-stranded CTG and CAG or CCTG and CAGG oligonucleotides as previously described52. 
Synthesized DNA duplexes were electrophoresed, size fractionated, purified using a DNA gel extraction kit 
(Qiagen), 5′-phosphorylated with T4 polynucleotide kinase, and cloned into the EcoRV site of pUAST. The 
recombinant plasmids containing uninterrupted stretches of CTG or CCTG repeats were amplified in STBL3 E. 
coli (Invitrogen) at 20 °C. Plasmid DNA was purified using a Qiagen plasmid DNA purification kit and sequenced 
from both ends to ensure the sequence integrity of the clones. Transgenic flies were generated by injecting the 
plasmids into w1118 embryos by BestGene Inc. following the method described in ref. 53. UAS-GFP strain was 
obtained from the Bloomington Drosophila Stock Center (Indiana University, Bloomington, IN). The cardio- 
myocyte-specific driver GMH5–Gal4 was kindly provided by Dr. Bodmer from the Sanford Burnham Institute, 
California, USA33. The Mhc-GAL4 line was previously described32. Mhc-Gal4 drives expression in terminally 
differentiated muscle under the control of endogenous myosin heavy chain regulatory regions, while GMH5-Gal4 
is expressed in cardiomyocytes initially driven by a 900 nt tinman heart enhancer and later maintained by a UAS- 
Gal4 autoregulatory loop33. All the fly lines were maintained in standard Drosophila food. The flies were grown 
at 25 °C to study the effect of expressing repeats throughout the musculature and at 29 °C to study the cardiac 
defects. Expression levels of the different transgenes were assessed as previously described35. 
 
Cardiac physiological analysis. For the physiological analysis, female flies were collected just after eclo- 
sion and were maintained for 7 days at 29 °C. For the heart-beat recordings, semi-intact heart preparations were 
made as previously described54, 55. An Leica DFC 450C microscope, connected to an ORCA Flash (Hamamatsu) 








Figure 6. Cardiac dysfunction in DM1 and DM2 model flies includes diastolic and systolic elongation, 
increased arrhythmicity, and reduced contractility. The mean heart period (HP, in A) was significantly increased 
in flies expressing expanded CUG or CCUG repeats in heart. This increase was caused by a prolongation of both 
diastolic and systolic intervals (DI, in B and SI, in C) in the model flies. Heart tube contractility and cardiac 
rhythm were also affected in these flies, because the percentage of fractional shortening (%FS in D) was reduced 
to only 20% and arrhythmia, measured as the arrhythmicity index (AI in E), was significantly increased to 
similar levels in both DM1 and DM2 model flies. Graph bars show the mean values and their standard errors 
(n= 18 to 29). *p< 0.05, **p < 0.01, ***p < 0.001 (Student’s t-test). 
 
high-speed digital camera was used to take 20 s recordings at a minimum speed of 150 frames/s. Different cardiac 
parameters were measured using SOHA software51. 
Histological analysis. Analysis of the IFM area in Drosophila thoraces was performed as previously 
described56. Briefly, six thoraces from three-day or thirty-day-old (aged group) females were embedded in Epon 
following standard procedures. After drying the resin, semi-thin 1.5 µm-sections were obtained using an ultrami- 
crotome (Ultracut E, Reichert-Jung and Leica). Images were taken at 100× magnification with a Leica DM2500 
microscope (Leica Microsystems, Wetzlar, Germany). To quantify the muscle area, five images containing IFMs 
per fly were converted into binary images. Considering the complete image as 100% of the area, we used ImageJ 
software to calculate the percentage occupied by pixels corresponding to the IFMs. The percentage of pixels occu- 
pied by muscle in the control GFP flies were considered as 100%, and the percentage of muscle area of the rest of 
genotypes were normalized to these control flies. 
For immunofluorescence analysis, dissected fly hearts or Drosophila thorax longitudinal sections were fixed 
for 20 min in 4% paraformaldehyde, and washed in PBT (PBS containing 0.3% Triton X-100) before staining. 
Muscleblind staining, and FISH to detect ribonuclear CUG foci, were performed as previously described56. The 








Figure 7. Expression of expanded CUG or CCUG repeats in fly heart alters survival but not locomotion. (A) 
Average percentage of live flies, with the indicated genotypes, versus age (in days). The GMH5-Gal4 driver 
was used to induce expression of the indicated genotypes in cardiomyocytes. Horizontal dotted line marks 
the median survival. Flies expressing expanded CUG (CUG(250)×; n= 100) or CCUG (CCUG(1100)×; 
n= 97) repeats had a reduced lifespan compared to control flies (GFP; n= 100) or flies expressing the short 
versions of the repeats (CUG(20)×; n= 95 and CCUG(20)×; n= 99). The differences in survival curves were 
highly significant (p< 0.0001, log-rank test). (B) Histogram showing the climbing velocity of flies as the mean 
speed ± SEM in mm/s. Expression of long CUG or CCUG repeats in heart did not modify climbing velocity 
compared to control flies or flies expressing the short versions of repeats. (C) Notched box plot showing the 
median and the distribution of the average landing height data obtained in the flight assay using flies with the 
genotypes indicated. *p< 0.05, **p< 0.01, ***p< 0.001 (Student’s t -test). 
 
 
specificity of the anti-Mbl antibody has been previously tested in ref. 56. To detect CCUG foci a variation of the 
FISH protocol was implemented using a locked nucleic acid (LNA) probe with 7 CAGG repeats (Sigma), which 
was hybridized at 55 °C. All the confocal images were taken with an Olympus FV1000 microscope. 
RNA extraction, RT-PCR and qRT-PCR. For each biological replicate, total RNA was extracted using 
Trizol (Sigma) from 10 five-day old adult males for the muscle studies and 20 seven-day old adult female hearts 
for the cardiac studies. One microgram of RNA was digested with DNase I (Invitrogen) and reverse-transcribed 
with SuperScript II (Invitrogen) using random hexanucleotides. 20 ng of cDNA were used in a standard PCR 
reaction with GoTaq polymerase (Promega) and specific primers to analyze Fhos exon 16′ inclusion (Table S1). 
Rp49 was used as endogenous control using 0.2 ng of cDNA. qRT-PCR to analyze Serca exon 13 and Atg 4, Atg7, 
Atg8a, Atg9 and Atg12 expression levels was carried out from 2 ng of cDNA template with SYBR Green PCR 
Master Mix (Applied Biosystems) and specific primers (Table S1). For reference gene, Rp49, qRT-PCR was car- 
ried out from 0.2 ng of cDNA. Thermal cycling was performed in Step One Plus Real Time PCR System (Applied 
Biosystems). Three biological replicates and three technical replicates per biological sample were carried out. 
Relative expression to endogenous gene and the control group was obtained by the 2−∆∆Ct method. Pairs of sam- 
ples were compared using two-tailed t-test (α= 0.05), applying Welch’s correction when necessary. 
Survival curves. Survival experiments were performed independently twice with a minimum of 45 flies each 
time. Flies were maintained at 25 °C for experiments involving Mhc-Gal4 and at 29 °C for the GMH5-Gal4 driver. 
The flies were transferred to new fresh nutritive media every second day and scored for deaths daily. 
Flight and climbing functional assays. Given the heterogeneity generally found in the functional assays 
performed with female flies, we only used males in these experiments. Flight assays were performed on day five 
as described previously57 using 100 flies per group. To assess climbing velocity, groups of 15, five-day-old males 
were transferred into 25 cm long, 1.5 cm diameter pipettes, after a period of 24 h without anesthesia. The height 
reached from the bottom of the vial by each fly in a period of 10 s was recorded with a camera. For each genotype, 
approximately 30 flies were tested. 
Statistical analysis. Statistical analysis was performed using GraphPad Prism5 software. Pairs of samples 
were compared using a two-tailed Student’s t-test (α = 0.05), applying Welch correction when necessary. The 
survival curves used a minimum of 90 individuals and a log-rank test was used to assess whether there were any 
significant differences between them. The flight assay data are represented as a notched box plot, which includes 
the median and the distribution of the average landing heights obtained; the horizontal lines inside the boxes 
represent the median values, the bottom and top edges of the boxes represent the 25th and 75th percentiles, and 
bottom and top whiskers reach the 10th and 90th percentiles, respectively. 
Discussion 
A significant feature of DM is that two different microsatellite expansions in two unrelated genes cause a clinically 
similar disease. The histological features of skeletal muscle biopsies taken from DM1 and DM2 patients are very 
similar50, 58. In both diseases, affected muscles show central nuclei, a reduction in the number and diameter of 
specific fiber types, fibrosis and adipose deposition. DM2 is specifically characterized by the presence of atrophic 
fibers with nuclear clumps even before the muscle weakness appearance as well as by a predominant type 2 fiber 





atrophy59, 60. In DM2, cardiac abnormalities have also been reported to be similar to those described in DM1, 
including conduction disturbances, cardiac arrhythmias and sudden death26, 61–63. Similarly, the characteristic 
features of DM that we describe in our DM2 (CCUG-repeat bearing) flies, including muscle and locomotor 
defects, cardiac dysfunction and reduced survival, were very similar to the characteristics of flies expressing CUG 
repeats. Interestingly, the phenotypic similarities between our DM1 and DM2 model flies go beyond phenotypes 
to the pathogenesis mechanisms. We showed that Mbl retention in foci resulting in missplicing, and autophagy 
activation are common to both diseases. We report that autophagy-related genes are upregulated not only in 
muscle, but also in heart in both models, suggesting that this is not a tissue-specific mechanism of repeat toxicity. 
Some important differences between both models are also highlighted in our study. The effect of the expression of 
long CCUG repeats in heart was more pronounced than that of long CUG repeats, and correlated with stronger 
upregulation of autophagy-related factors. These data suggest the existence of unknown tissue-dependent fac- 
tors that might modulate the toxicity of CUG and CCUG repeats. The difference between the expression level 
of autophagy-related factors in control or expanded repeat-expressing flies was higher in muscle compared to 
heart samples, suggesting that autophagy is importantly involved in pathogenesis in this tissue. The autophagy 
activation in the DM1 and DM2 model flies coincides in muscle with strong muscle area reduction in the flies 
expressing the long versions of the repeats. These data are consistent with our previous results in the model flies 
expressing 480 CUG repeats34. Moreover, our experiments with young and aged flies have shown that muscle 
defects caused by expanded CCUG repeats have not only a developmental contribution but may also impinge on 
adult muscle maintenance and/or degeneration, as we have previously shown with heat-shock-induced expres- 
sion of CUG expansions exclusively in adult muscle34. Importantly, this is the first DM2 animal model showing 
obvious muscle phenotypes. 
As a result of expanded repeats expression in heart, we observed systolic and diastolic dysfunction, reduction 
of the fractional shortening and increased arrhythmicity in DM2 model flies, which resembled the DM1-like 
phenotype previously described in flies35 and in DM patients64. Importantly, SI and DI were more affected by 
CCUG repeats than by CUG repeats expression. Accordingly, in heart tissue, the expression of short repeats 
produced a slight but significant prolongation in the systolic interval, which was more pronounced in the case 
of CCUG-expressing flies. Remarkably, the expression of short versions of repeats did not induce Muscleblind 
sequestration in foci in IFM or heart tissue. Therefore, the phenotypes observed in these flies might be independ- 
ent of Muscleblind, and the factors originating the phenotype seem to be more sensitive to CCUG repeats than 
to CUG repeats. 
An open question in the field of DM is to clarify the pathomechanisms underlying the phenotypic differences 
between DM1 and DM2. Several studies have confirmed that the frequency and severity of cardiac involvement 
and of muscle weakness are reduced in DM2 compared to DM1 and that progression is slower and less severe in 
DM224, 26. This suggests that other cellular and molecular pathways are involved besides the shared toxic-RNA 
gain of function in the human disease phenotype. Three factors have been shown to influence the level of tox- 
icity of expanded repeats in the RNA; expression level, length, and sequence21, 65, 66. Longer sequences tend to 
cause severe pathogenesis but depending on the sequence, RNA binding factors might be differentially affected. 
Importantly, in DM2 patients, the severity of the disease has not been directly correlated with the repeat number, 
only a relationship between repeat lengths and MBNL1 rate of sequestration has been established21. In flies, how- 
ever, a previous report showing the effect in eye of the expression of pure, uninterrupted CCUG-repeat expan- 
sions ranging from 16 to 720 repeats in length, has shown a nice correlation between length and toxicity of the 
CCUG repeats22. We believe that this previous observation, and our own reports of similar phenotypes in flies 
expressing either expanded CUG or CCUG repeats, suggest the existence of unknown modifiers in humans, 
which might quench RNA toxicity in DM2 patients. 
In our flies expressing 250 CUG repeats we observed very similar phenotypes but milder than the ones previ- 
ously reported by expressing 480 interrupted CUG repeats in muscle34, 49. Our data suggests that these phenotypes 
are sensitive to CUG repeat length, a main feature of DM1, and suggest that the phenotypes described in the 
previous model were not significantly affected by interrupting sequences. 
The experiments expressing the CUG or CCUG repeats in a non-human context in Drosophila provide evi- 
dence of the strong toxicity potential of the CCUG repeats, as the phenotypes we report in the DM2 model flies 
expressing the repeats in muscle or heart, are as strong as the phenotypes obtained from expressing the CUG 
repeats. Disease-specific manifestations may then result from factors that are extrinsic to the repeats and previous 
evidence suggested several hypotheses. Disease-specific manifestations may result from differences in spatial and 
temporal expression patterns of DMPK and CNBP genes. Similarly, changes in the expression of neighboring 
genes may define disease-specific manifestations. It was recently reported that CUGBP1 protein is overexpressed 
in muscle biopsies from patients affected by the adult classical form of DM1 but not in muscle from DM2 patients, 
suggesting that CUGBP1 overexpression in DM1 might be an additional pathogenic mechanism not shared by 
DM267. Another possible explanation for the clinical differences between the two DM forms is the reduction of 
DMPK or ZNF9 protein levels in DM1 and DM2 respectively68–70. However, Dmpk knockout young mice do 
not develop a multisystemic phenotype mimicking myotonic dystrophy71. On the contrary, reduction of CNBP 
levels is sufficient to produce multiorgan symptoms resembling those of DM as observed in heterozygous Cnbp 
+/− knockout mice72 implying that CNBP may well play a role in DM2 pathology21. According to different 
sources, CNBP is 4 to 8-fold more expressed in human muscles than the DMPK gene27–29, which makes it difficult 
to explain the phenotypic differences between DM1 and DM2 based on the small reductions in CNBP expression 
reported in DM2 patients. Another important difference between CUG and CCUG expansions is that MBNL 
has been reported to bind CCUG repeats with a stronger affinity compared to CUG repeats6, 30. In addition, the 
ribonuclear inclusions in DM2 patients appear to be larger than in DM1 patients, and sequester more MBNL21. 
Accordingly, our results in the DM model flies show that, at least in muscle, flies expressing expanded CCUG 
repeats tend to have higher levels of missplicing, suggesting a reduced activity of Mbl. However, the muscle 





defects in DM1 and DM2 model flies were similar, suggesting that Mbl involvement in muscle phenotype is 
already limiting in DM1 model flies and decreasing levels of Mbl would not result in stronger phenotype. 
In conclusion, through this demonstration of CUG and CCUG repeat-induced toxicity in different fly tissues 
we have gained a useful insight into the differences and similarities in the mechanism of DM pathogenesis in 
these tissues. The dual system we report (DM1 vs DM2 fly model) with well-characterized repeat expression, 
resulting phenotypes and molecular alterations, will also be useful to compare the effect of potential chemical 
or genetic modifiers of RNA toxicity on each of these diseases. The potential discovery of genetic modifiers that 
affect only one of the components in flies, either CUG or CCUG toxicity, could explain the clinical differences 
between both human diseases, contributing to increase the knowledge about their pathogenesis pathways and 
towards the development of new treatments. 
References 
1. Brook, J. D. et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript 
encoding a protein kinase family member. Cell 69, 385 (1992). 
2. Ricker, K. et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 
44, 1448–1452, doi:10.1212/WNL.44.8.1448 (1994). 
3. Liquori, C. L. et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293, 864–867, doi:10.1126/ 
science.1062125 (2001). 
4. Meola, G. & Cardani, R. Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms. 
Biochimica et biophysica acta 1852, 594–606, doi:10.1016/j.bbadis.2014.05.019 (2015). 
5. Miller, J. W. et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. Embo 
J 19, 4439–4448, doi:10.1093/emboj/19.17.4439 (2000). 
6. Kino, Y. et al. Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats. Human molecular genetics 13, 495–507, 
doi:10.1093/hmg/ddh056 (2004). 
7. Mankodi, A. et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Human molecular 
genetics 10, 2165–2170, doi:10.1093/hmg/10.19.2165 (2001). 
8. Fardaei, M. et al. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in 
DM1 and DM2 cells. Human molecular genetics 11, 805–814, doi:10.1093/hmg/11.7.805 (2002). 
9. Jiang, H., Mankodi, A., Swanson, M. S., Moxley, R. T. & Thornton, C. A. Myotonic dystrophy type 1 is associated with nuclear foci of 
mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Human molecular genetics 13, 
3079–3088, doi:10.1093/hmg/ddh327 (2004). 
10. Cardani, R., Mancinelli, E., Rotondo, G., Sansone, V. & Meola, G. Muscleblind-like protein 1 nuclear sequestration is a molecular 
pathology marker of DM1 and DM2. European journal of histochemistry: EJH 50, 177–182 (2006). 
11. Lukas, Z. et al. Sequestration of MBNL1 in tissues of patients with myotonic dystrophy type 2. Neuromuscular disorders: NMD 22, 
604–616, doi:10.1016/j.nmd.2012.03.004 (2012). 
12. Timchenko, N. A. et al. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 276, 
7820–7826, doi:10.1074/jbc.M005960200 (2001). 
13. Goodwin, M. & Swanson, M. S. RNA-binding protein misregulation in microsatellite expansion disorders. Adv Exp Med Biol 825, 
353–388, doi:10.1007/978-1-4939-1221-6_10 (2014). 
14. Wang, E. T. et al. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res 25, 858–871, 
doi:10.1101/gr.184390.114 (2015). 
15. Kino, Y. et al. MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1. Nucleic Acids 
Res 37, 6477–6490, doi:gkp681 (2009). 
16. Santoro, M. et al. Molecular, clinical, and muscle studies in myotonic dystrophy type 1 (DM1) associated with novel variant CCG 
expansions. Journal of neurology 260, 1245–1257, doi:10.1007/s00415-012-6779-9 (2013). 
17. Gao, Z. & Cooper, T. A. Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in 
myotonic dystrophy. Proceedings of the National Academy of Sciences of the United States of America 110, 13570–13575, 
doi:1308806110 (2013). 
18. Tang, Z. Z. et al. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 
calcium channel. Human molecular genetics 21, 1312–1324, doi:ddr568 (2012). 
19. Fugier, C. et al. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic 
dystrophy. Nat Med 17, 720–725, doi:nm.237 (2011). 
20. Martorell, L. et al. Germline mutational dynamics in myotonic dystrophy type 1 males: allele length and age effects. Neurology 62, 
269–274, doi:10.1212/WNL.62.2.269 (2004). 
21. Cardani, R. et al. Progression of muscle histopathology but not of spliceopathy in myotonic dystrophy type 2. Neuromuscular 
disorders: NMD 24, 1042–1053, doi:10.1016/j.nmd.2014.06.435 (2014). 
22. Yu, Z. et al. A fly model for the CCUG-repeat expansion of myotonic dystrophy type 2 reveals a novel interaction with MBNL1. 
Human molecular genetics 24, 954–962, doi:10.1093/hmg/ddu507 (2015). 
23. Milone, M., Batish, S. D. & Daube, J. R. Myotonic dystrophy type 2 with focal asymmetric muscle weakness and no electrical 
myotonia. Muscle & nerve 39, 383–385, doi:10.1002/mus.21150 (2009). 
24. Meola, G. & Moxley, R. T. 3rd Myotonic dystrophy type 2 and related myotonic disorders. Journal of neurology 251, 1173–1182, 
doi:10.1007/s00415-004-0590-1 (2004). 
25. Schoser, B. & Timchenko, L. Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms. Current genomics 11, 
77–90, doi:10.2174/138920210790886844 (2010). 
26. Sansone, V. A. et al. The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes. 
Int J Cardiol 168, 1147–1153, doi:10.1016/j.ijcard.2012.11.076 (2013). 
27. Wu, C., Jin, X., Tsueng, G., Afrasiabi, C. & Su, A. I. BioGPS: building your own mash-up of gene annotations and expression profiles. 
Nucleic Acids Res 44, D313–316, doi:10.1093/nar/gkv1104 (2016). 
28. Wu, C., Macleod, I. & Su, A. I. BioGPS and MyGene.info: organizing online, gene-centric information. Nucleic Acids Res 41, 
D561–565, doi:10.1093/nar/gks1114 (2013). 
29. Wu, C. et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 10, 
R130, doi:10.1186/gb-2009-10-11-r130 (2009). 
30. Warf, M. B. & Berglund, J. A. MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA 
substrate cardiac troponin T. Rna (2007). 
31. Bachinski, L. L. et al. Premutation allele pool in myotonic dystrophy type 2. Neurology 72, 490–497, doi:01.wnl.0000333665.01888.33 
(2009). 
32. Marek, K. W. et al. A genetic analysis of synaptic development: pre- and postsynaptic dCBP control transmitter release at the 
Drosophila NMJ. Neuron 25, 537–547, doi:10.1016/S0896-6273(00)81058-2 (2000). 





33. Wessells, R. J. & Bodmer, R. Screening assays for heart function mutants in Drosophila. BioTechniques 37, 58–60, 62, 64 passim 
(2004). 
34. Bargiela, A. et al. Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila 
model. Disease models & mechanisms 8, 679–690, doi:8/7/679 (2015). 
35. Chakraborty, M. et al. Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart 
dysfunction. Disease models & mechanisms 8, 1569–1578, doi:10.1242/dmm.021428 (2015). 
36. Lin, X. et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Human molecular genetics 15, 
2087–2097, doi:10.1093/hmg/ddl132 (2006). 
37. Cerro-Herreros, E., Fernandez-Costa, J. M., Sabater-Arcis, M., Llamusi, B. & Artero, R. Derepressing muscleblind expression by 
miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila. Sci Rep 6, 36230, doi:10.1038/srep36230 (2016). 
38. Picchio, L., Plantie, E., Renaud, Y., Poovthumkadavil, P. & Jagla, K. Novel Drosophila model of myotonic dystrophy type 1: 
phenotypic characterization and genome-wide view of altered gene expression. Human molecular genetics 22, 2795–2810, doi:ddt127 
(2013). 
39. Loro, E. et al. Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells. Cell Death Differ 17, 
1315–1324, doi:cdd201033 (2010). 
40. Vignaud, A. et al. Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions is associated with the 
activation of the ubiquitin-proteasome pathway. Neuromuscular disorders: NMD 20, 319–325, doi:S0960-8966(10)00111-2 (2010). 
41. Denis, J. A. et al. mTOR-dependent proliferation defect in human ES-derived neural stem cells affected by myotonic dystrophy type 
1. J Cell Sci 126, 1763–1772, doi:jcs.116285 (2013). 
42. Batra, R. et al. Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. 
Mol Cell 56, 311–322, doi:S1097-2765(14)00682-0 (2014). 
43. Goodwin, M. et al. MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain. Cell Rep 12, 
1159–1168, doi:S2211-1247(15)00789-5 (2015). 
44. Brockhoff, M. et al. Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I. J Clin 
Invest 127, 549–563, doi:10.1172/JCI89616 (2017). 
45. Udd, B. & Krahe, R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11, 891–905, 
doi:S1474-4422(12)70204-1 (2012). 
46. Chelly, J. & Desguerre, I. Progressive muscular dystrophies. Handb Clin Neurol 113, 1343–1366, doi:10.1016/B978-0-444-59565- 
2.00006-X (2013). 
47. Mathieu, J., Allard, P., Potvin, L., Prevost, C. & Begin, P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. 
Neurology 52, 1658–1662, doi:10.1212/WNL.52.8.1658 (1999). 
48. Breton, R. & Mathieu, J. Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with 
myotonic dystrophy. The Canadian journal of cardiology 25, e23–27, doi:10.1016/S0828-282X(09)70479-9 (2009). 
49. Garcia-Lopez, A. et al. Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS ONE 3, e1595, doi:10.1371/ 
journal.pone.0001595 (2008). 
50. Harper, P. Myotonic dystrophy. (Saunders, 2001). 
51. Cammarato, A., Ocorr, S. & Ocorr, K. Enhanced assessment of contractile dynamics in Drosophila hearts. BioTechniques 58, 77–80, 
doi:10.2144/000114255 (2015). 
52. Ordway, J. M. & Detloff, P. J. In vitro synthesis and cloning of long CAG repeats. BioTechniques 21, 609–610, 612 (1996). 
53. Spradling, A. C. & Rubin, G. M. Transposition of cloned P elements into Drosophila germ line chromosomes. Science 218, 341–347, 
doi:10.1126/science.6289435 (1982). 
54. Magny, E. G. et al. Conserved regulation of cardiac calcium uptake by peptides encoded in small open reading frames. Science 341, 
1116–1120, doi:10.1126/science.1238802 (2013). 
55. Ocorr, K. A., Crawley, T., Gibson, G. & Bodmer, R. Genetic variation for cardiac dysfunction in Drosophila. PLoS One 2, e601, 
doi:10.1371/journal.pone.0000601 (2007). 
56. Llamusi, B. et al. Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model. 
Disease models & mechanisms 6, 184–196, doi:dmm.009563 (2013). 
57. Babcock, D. T. & Ganetzky, B. An improved method for accurate and rapid measurement of flight performance in Drosophila. 
Journal of visualized experiments: JoVE e51223, doi:10.3791/51223 (2014). 
58. Day, J. W. et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60, 657–664, doi:10.1212/01. 
WNL.0000054481.84978.F9 (2003). 
59. Schoser, B. G. et al. Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle & nerve 29, 275–281, doi:10.1002/ 
mus.10545 (2004). 
60. Pisani, V. et al. Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2. Muscle & 
nerve 38, 1405–1411, doi:10.1002/mus.21122 (2008). 
61. Schmacht, L. et al. Cardiac Involvement in Myotonic Dystrophy Type 2 Patients With Preserved Ejection Fraction: Detection by 
Cardiovascular Magnetic Resonance. Circulation. Cardiovascular imaging 9, e004615, doi:10.1161/CIRCIMAGING.115.004615 
(2016). 
62. Lau, J. K., Sy, R. W., Corbett, A. & Kritharides, L. Myotonic dystrophy and the heart: A systematic review of evaluation and 
management. Int J Cardiol 184, 600–608, doi:10.1016/j.ijcard.2015.03.069 (2015). 
63. Petri, H., Vissing, J., Witting, N., Bundgaard, H. & Kober, L. Cardiac manifestations of myotonic dystrophy type 1. Int J Cardiol 160, 
82–88, doi:S0167-5273(11)00878-3 (2012). 
64. McNally, E. M. & Sparano, D. Mechanisms and management of the heart in myotonic dystrophy. Heart 97, 1094–1100, doi:10.1136/ 
hrt.2010.214197 (2011). 
65. Mastroyiannopoulos, N. P. et al. The effect of myotonic dystrophy transcript levels and location on muscle differentiation. Biochem 
Biophys Res Commun 377, 526–531, doi:10.1016/j.bbrc.2008.10.031 (2008). 
66. Botta, A. et al. The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 
1 patients. Journal of medical genetics 45, 639–646, doi:10.1136/jmg.2008.058909 (2008). 
67. Cardani, R. et al. Overexpression of CUGBP1 in skeletal muscle from adult classic myotonic dystrophy type 1 but not from myotonic 
dystrophy type 2. PLoS One 8, e83777, doi:10.1371/journal.pone.0083777 (2013). 
68. Huichalaf, C. et al. Reduction of the rate of protein translation in patients with myotonic dystrophy 2. J Neurosci 29, 9042–9049, 
doi:10.1523/JNEUROSCI.1983-09.2009 (2009). 
69. Raheem, O. et al. Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy 
type 2. The American journal of pathology 177, 3025–3036, doi:10.2353/ajpath.2010.100179 (2010). 
70. Kaliman, P. & Llagostera, E. Myotonic dystrophy protein kinase (DMPK) and its role in the pathogenesis of myotonic dystrophy 1. 
Cellular signalling (2008). 
71. Carrell, S. T. et al. Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice. 
Human molecular genetics 25, 4328–4338, doi:10.1093/hmg/ddw266 (2016). 
72. Chen, W. et al. Haploinsuffciency for Znf9 in Znf9+/− mice is associated with multiorgan abnormalities resembling myotonic 
dystrophy. Journal of molecular biology 368, 8–17, doi:10.1016/j.jmb.2007.01.088 (2007). 






We thank Dr. Ocorr and Dr. Bodmer (Sanford Burnham Prebys Medical Discovery Institute, USA) for the 
development of the freely available SOHA software and Dr. Nicholas Charlet Berguerand (Institut de Génétique et 
de Biologie Moléculaire et Cellulaire, France) for providing us with the different CTG and CCTG plasmid versions. 
This study was co-funded by grants from the Instituto de Salud Carlos III, Spain (PI13/00386, including funds 
from ERDF) and the ERA-Net E-Rare framework from ISCIII (PI12/03106 including funds from ERDF) upon the 
AES (R + D + I) National Plan of Spain awarded to MPA and BL, respectively. Additional financial support was 
from P73 project “Todos somos raros, todos somos Unicos”, RTVE TELEMARATON (FEDER, FUNDACION 
ISABEL GEMIO and ASEM) to BL and PROMETEOII/2014/067 to RA. ECH was supported by a pre-doctoral 
fellowship (BES-2013–064522) from the Ministerio de Economia y Competitividad, Spain. MC was the recipient 
of a Santiago Grisolía award (GrisoliaP/2013/A/044). 
Author Contributions 
B.L.L., R.A. and M.P.A. conceived and designed the experiments. B.L.L., E.C.H., and M.C. performed the 
experiments and analyzed the data. B.L.L. and R.A. wrote the paper with contributions from all the authors. 
Additional Information 
Supplementary information accompanies this paper at doi:10.1038/s41598-017-02829-3 
Competing Interests: The authors declare that they have no competing interests. 
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations. 
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre- 
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per- 
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. 








Correction: Daunorubicin reduces MBNL1 sequestration caused 
by CUG-repeat expansion and rescues cardiac dysfunctions in a 
Drosophila model of myotonic dystrophy (doi: 10.1242/ 
dmm.032557) 
 
Mouli Chakraborty, Chantal Sellier, Michel Ney, Pascal Villa, Nicolas Charlet-Berguerand, Ruben Artero, Beatriz Llamusi 
There was an error published in Dis. Model Mech. 11, dmm032557 (doi: 10.1242/dmm.032557) 








































This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and 
reproduction in any medium provided that the original work is properly attributed. 




























Daunorubicin reduces MBNL1 sequestration caused by 
CUG-repeat expansion and rescues cardiac dysfunctions in a 
Drosophila model of myotonic dystrophy 
Mouli Chakraborty1,2,3, Chantal Sellier4, Michel Ney4, Villa Pascal5, Nicolas Charlet-Berguerand4, 




Myotonic dystrophy (DM) is a dominantly inherited neuromuscular 
disorder caused by expression of mutant myotonin-protein kinase 
(DMPK) transcripts containing expanded CUG repeats. Pathogenic 
DMPK RNA sequesters the muscleblind-like (MBNL) proteins, causing 
alterations in metabolism of various RNAs. Cardiac dysfunction 
represents the second most common cause of death in DM type 1 
(DM1) patients. However, the contribution of MBNL sequestration in 
DM1 cardiac dysfunction is unclear. We overexpressed Muscleblind 
(Mbl), the Drosophila MBNL orthologue, in cardiomyocytes of DM1 
model flies and observed a rescue of heart dysfunctions, which are 
characteristic of these model flies and resemble cardiac defects 
observed in patients. We also identified a drug – daunorubicin 
hydrochloride – that directly binds to CUG repeats and alleviates Mbl 
sequestration in Drosophila DM1 cardiomyocytes, resulting in mis- 
splicing rescue and cardiac function recovery. These results 
demonstrate the relevance of Mbl sequestration caused by 
expanded-CUG-repeat RNA in cardiac dysfunctions in DM1, and 
highlight the potential of strategies aimed at inhibiting this protein-RNA 
interaction to recover normal cardiac function. 
KEY WORDS: Daunorubicin, Drosophila, Muscleblind, Myotonic 





Myotonic dystrophy type 1 [DM1; Online Mendelian Inheritance of 
Man (OMIM) 160900] is the most common muscular dystrophy in 
adults (Harper, 2001; Smith and Gutmann, 2016). Presently, DM1 
has no effective treatment, but several therapeutic options are being 
explored (Rzuczek et al., 2017; Gao et al., 2016; Bisset et al., 2015; 
Konieczny et al., 2017). Although DM1 mainly affects skeletal 
muscle, cardiac involvement occurs in 80% of DM1 patients and 
represents the second most common cause of death after respiratory 
failure (Vinereanu et al., 2004). Three interrelated cardiac phenotypes 
are observed in individuals with DM1. The first are conduction 
defects, which can progress to complete heart blockage (Nguyen  
et al., 1988). The second is the development of potentially fatal 
ventricular and/or atrial arrhythmias (Nigro et al., 2012; Benhayon 
et al., 2015). The third type of cardiac dysfunction observed in DM1, 
although rarer, is mechanical diastolic and/or systolic dysfunction that 
can progress to combined systolic and diastolic heart failure (Phillips 
and Harper, 1997; Mathieu et al., 1999; Lazarus et al., 2002; Groh 
et al., 2008). The genetic cause of DM1 is an expansion of CTG 
repeats in the 3′UTR of the DMPK gene (Brook et al., 1992; Fu et al., 
1992; Mahadevan et al., 1992). This microsatellite expansion is 
transcribed into mutant DMPK mRNA that contains hundreds to 
thousands of CUG repeats that are toxic through dysfunction of at 
least  two  RNA-binding  proteins.  The  muscleblind-like (MBNL) 
family of proteins, comprising MBNL1, MBNL2 and MBNL3, 
normally bind to YGC (Y stands for pyrimidine) RNA motifs and are 
diverted away from their normal RNA targets by the expanded CUG 
RNA repeats in DMPK transcripts (Miller et al., 2000; Mankodi et al., 
2001; Fardaei et al., 2002; Ho et al., 2004; Lin et al., 2006; Wang 
et al., 2015). Furthermore, expanded CUG repeats also induce 
hyperphosphorylation and increase stabilization of CUG-binding 
protein 1 (CELF1; also named CUGBP1) (Kuyumcu-Martinez et al., 
2007). As a result of disrupting the function of these proteins, various 
mis-regulations in RNA metabolism have been described in 
individuals with DM1, some of which are associated with specific 
symptoms of the disease (Mankodi et al., 2002; Savkur et al., 2001; 
Tang et al., 2012; Fugier et al., 2011; Freyermuth et al., 2016). 
Reduced MBNL function appears to be a key pathogenic event 
underlying the skeletal muscle alterations observed in DM1 
   (Kanadia et al., 2003; Nakamori et al., 2013; Wagner et al., 
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2016). Indeed, overexpression of MBNL1 rescues DM1-like 
skeletal muscle alterations in a mouse model of DM1 (Kanadia   
et al., 2006). Furthermore, compounds or strategies aimed at 
reducing MBNL1 binding to expanded CUG repeats alleviate 
skeletal muscle dysfunctions in cell and animal models of DM1 
(Warf et al., 2009; García-López et al., 2011; Childs-Disney et al., 
2013; Cerro-Herreros et al., 2016). In contrast, the molecular causes 
of cardiac dysfunction in DM1 and the involvement of MBNL 
proteins in these defects are not yet fully understood. Notably, 
compound loss of Mbnl1 and Mbnl2 in mice generated cardinal 
features of DM1, including heart conduction dysfunction (Lee et al., 
2013). However, elevation of CUGBP1 is an early event in the heart 
of a mouse model of DM1 (Wang et al., 2007), and heart-specific 
overexpression of CUGBP1 in mice induces functional and 
molecular alterations (Koshelev et al., 2010). Furthermore, 
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inhibition of CUGBP1 hyperphosphorylation ameliorates the cardiac 
phenotype in a mouse model of DM1 (Wang et al., 2009). Importantly, 
both MBNL and CUGBP1 are master switches for normal heart 
development as they regulate a large subset of alternative splicing 
transitions that occur post-natally (Wang et al., 2015; Kalsotra et al., 
2008). These data suggest that the pathogenic events underlying the 
cardiac dysfunctions in DM1 remain to be fully defined. 
To study the importance of MBNL proteins in the heart 
dysfunction induced by expanded CUG repeats in DMPK, we 
used a Drosophila model expressing pure expanded CUG repeats 
(250 CUG repeats) in cardiomyocytes (Chakraborty et al., 2015). 
Importantly, cardiac dysfunction described in these flies is 
completely reversed by the sole overexpression of Mbl, the 
Drosophila orthologue of MBNL proteins. To further support the 
relevance of this protein in DM1 cardiac dysfunction, we searched 
in vitro for compounds that inhibit the interaction between MBNL1 
and expanded CUG repeats. One of these compounds, daunorubicin 
hydrochloride, releases endogenous Mbl from CUG RNA foci by 
directly binding to CUG RNA, resulting in the correction of Mbl- 
dependent splicing alterations and subsequent recovery of heart 
dysfunction and survival in DM1 flies. These data highlight not 
only the relevance of MBNL depletion related to heart dysfunction 
in DM1, but also provide evidence that strategies aimed at releasing 
MBNL proteins from expanded CUG RNA repeats might also be 
useful to treat cardiac dysfunction in DM1. 
 
RESULTS 
Muscleblind is sufficient to rescue the cardiac dysfunctions 
and reduced survival caused by expanded CUG repeats 
To understand the role of Mbl in cardiac dysfunction induced by 
expanded CUG repeat expression, we generated recombinant flies 
that simultaneously expressed 250 pure CUG repeats and either Mbl 
isoform C (MblC; the best evolutionary conserved Mbl isoform in 
Drosophila) or green fluorescent protein (GFP), as control. Cardiac 
parameters were analyzed using semi-automated optical heartbeat 
analysis (SOHA) software on 7-day-old female flies as described 
previously (Chakraborty et al., 2015; Ocorr et al., 2014; Cerro- 
Herreros et al., 2017). Heart dysfunctions, including systolic and 
diastolic dysfunction, arrhythmia and reduced contractility, in DM1 
model flies expressing GFP were identical to DM1 flies (Fig. S1) 
and were similar to the previously reported alterations (Chakraborty 
et al., 2015), indicating that the expression of the GFP reporter is 
innocuous in heart. In contrast to GFP, expression of MblC corrects 
the cardiac parameters of DM1 flies: Drosophila expressing 250 
pure CUG repeats and MblC were similar to control flies that do not 
express the repeats. Notably, MblC expression rescued heart period 
length [HP; defined as the diastolic interval (DI) plus systolic 
interval (SI)] (Fig. 1A-C), mainly by a 2-fold reduction of the SI (the 
contraction period). The variability in the heart periodicity, 
quantified as ‘arrhythmia index’ (AI), and the heart contractility, 
or percentage of fractional shortening (%FS), were also rescued in 
DM1 flies by MblC overexpression (Fig. 1D,E). Finally, survival, 
which was decreased in DM1 model flies, was also corrected by 
MblC, with median survival increasing from 22 to 32 days, and the 
lifespan increasing from 31 to 50 days (Fig. 1F). These results 
support an important role of Mbl loss of function in the heart 
dysfunctions induced by expression of expanded CUG repeats. 
 
Identification of compounds reducing MBNL1 binding to CUG 
repeats 
To confirm the relevance of MBNL loss of function in cardiac 
dysfunctions in DM1, we developed a real-time fluorescence 
 
 
Fig. 1. Cardiac dysfunction and survival are rescued by MblC 
overexpression in DM1 model flies. In comparison to control flies expressing 
GFP, the heart period mean (HP; in A) increased in flies expressing expanded 
CUG repeats and GFP [CUG(250)× GFP] together. Increased HP is caused by 
extended diastolic and systolic intervals (DI and SI; in B and C, respectively). In 
contrast, simultaneous expression of CUG repeats and MblC [CUG(250)× 
MblC] achieved a reduction of HP length by a large decrease of SI. Heart 
contractility, measured as percentage of fractional shortening (%FS; in D), and 
arrhythmicity, measured as arrhythmia index (AI; in E), which were altered in 
DM1 flies, were also rescued by MblC overexpression (n=18 to 29). Median 
survival and lifespan were also rescued by MblC overexpression (F; n≈50). 
***P<0.001, **P<0.01, *P<0.05, ns, not significant (Student’s t-test). 
 
 
polarization/anisotropy assay to identify pharmacological 
compounds reducing MBNL1 binding to pathogenic CUG repeats. 
Fluorescence polarization measures the degree of polarization of a 
fluorophore, reflecting its rotational diffusion, a parameter that is 
inversely proportional to the molecule volume and thus reflects the 
molecular mass of the fluorescent-labelled molecule or complex. In 
short, fluorescence polarization can discriminate between a 
fluorescent-labelled RNA free in solution compared to the same 
RNA in complex with an RNA-binding protein. Consequently, a 
molecule that disrupts the binding between a fluorescent RNA and a 
protein can be identified by a reduction of the fluorescence 
polarization. In our assay, we used a chemically synthetized CUG 
repeat (26 repeats) RNA labelled with a tetramethylrhodamine and 
incubated with purified recombinant GST-MBNL1-HIS produced 
from Escherichia coli. An optimal shift of fluorescent polarization 
was observed with 50 nM of fluorescent CUG RNA incubated with 
400 nM of recombinant MBNL1 protein. We screened in 96-well 
plates and at 10 µM final concentration ∼6500 compounds from two 
libraries, the Strasbourg Academic library, consisting of ∼5300 
chemical or natural substances, and the Prestwick library, consisting 
of 1200 drugs approved by regulatory agencies. From this screen, we 
identified 76 molecules, of which 12 were verified by fluorescent 
polarization to inhibit binding of MBNL1 to CUG-repeat RNA in 
vitro (Fig. 2A). Next, we tested whether these compounds can reduce 
the sequestration of MBNL1 in human cultured cells. The 
colocalization of endogenous MBNL1 with foci of expanded CUG 
RNA was assessed by immunofluorescence coupled to RNA 
fluorescent in situ hybridisation (FISH) in primary cultures of 





























DM1. Among the 12 compounds tested, three compounds – C2, C5 
and C6 – decreased the sequestration of MBNL1 in cellulo (Fig. 2B). 
However, C5 was toxic and not investigated further (Fig. 2C). 
Subsequent studies in DM1 primary muscle cell cultures revealed that 
compound C6, daunorubicin hydrochloride, was achieving the most 
important reduction of MBNL1 colocalization with CUG RNA foci. 
Addition of 3-10 µM of daunorubicin reduced the colocalization of 
MBNL1 with CUG RNA foci by 20-30% in DM1 primary muscle 
cell cultures, but with some toxicity (Fig. 2D,E). Of note, 
daunorubicin treatment of control or DM1 primary muscle cell 
cultures did not modify protein expression of MBNL1, nor the 
mRNA expression of DMPK (Fig. S2A,B). We also quantified foci 
number in human DM1 fibroblasts (Arandel et al., 2017) at increasing 
 
 
Fig. 2. Validation screening of the 76 compounds tested at a 
concentration of 10 µM in DMSO to identify molecules reducing binding 
of MBNL1 to expanded-CUG-repeat RNA. (A) Fluorescence polarization of 
TRITC-labelled (CUG)26× RNA alone or in complex with GST-MBNL1-HIS 
recombinant protein is indicated by orange or blue dots, respectively. N=3 
independent assays. (B) Percent of CUG RNA foci presenting a colocalization 
with endogenous MBNL1 in cultures of DM1 myoblasts upon drug treatment at 
10 µM in DMSO for 24 h. N=3 independent cultures; 30 RNA foci were 
analyzed in each experiment. (C) Percent of living DM1 myoblasts upon drug 
treatment at 10 µM in DMSO for 24 h. (D) Percent of CUG RNA foci showing 
colocalization with endogenous MBNL1 in cultures of DM1 myoblasts upon 
daunorubicin treatment at 0.3, 1, 3 and 10 µM in DMSO for 24 h. N=4 
independent cultures; at least 50 cells were analyzed each time. (E) Percent of 
living DM1 myoblasts upon daunorubicin treatment at 0.3, 1, 3 and 10 µM in 
DMSO for 24 h. (F-H) Foci detection in DM1 fibroblasts. Representative 
confocal images of FISH in DM1 fibroblasts treated with DMSO as control (F) or 
daunorubicin (G) showed reduced number of foci (red in F and G) with 
daunorubicin treatment. Nuclei were counterstained with DAPI (blue). 
(H) Quantification of foci confirmed a statistically significant difference at 
concentrations of daunorubicin higher than 1 µM. For all figure panels, error 
bars indicate s.e.m. Student’s t-test: *P<0.05; **P<0.01; ***P<0.001. 
 
concentrations of daunorubicin, and observed a significant reduction 
of foci number at concentrations higher than 1 µM (Fig. 2F-H). These 
data encouraged us to test whether daunorubicin could correct any 
phenotypic alterations in an animal model of DM1. 
 
Daunorubicin rescues cardiac dysfunction and fly survival in 
DM1 model flies 
Daunorubicin is a double-stranded DNA or RNA intercalant that 
belongs to the anthracyclines family. It has been used as curative or 
palliative treatment for several types of cancer for over 30 years 
(Hande, 1998; Gewirtz, 1999; Ellison et al., 1991; Kоbylinska et al., 
2016). To assess the potential of daunorubicin to rescue DM1 cardiac 
phenotypes, we fed DM1 model flies with the compound diluted in 
1% DMSO to a final concentration of 1 μM in nutritive media. We had 
previously shown that, at the concentration used, DMSO does not alter 
the cardiac parameters in Drosophila (Chakraborty et al., 2015). For 
cardiac function assessment, 7-day-old flies fed with the compound 
were dissected to expose the beating heart in artificial aerated 
haemolymph, and videos were taken and analyzed by SOHA software 
(Chakraborty et al., 2015; Ocorr et al., 2014; Cerro-Herreros et al., 
2017). In all analyses, flies that do not express CUG repeats but 
expressed GFP were used as controls. As compared to the DMSO-fed 
model flies, flies fed with daunorubicin showed significant 
improvement in HP length (Fig. 3A), with a significant 2-fold 
decrease in both the DI and SI (Fig. 3B,C). Furthermore, daunorubicin 
corrected AI (Fig. 3E), which decreased by almost 3-fold in treated 
flies, and rescued heart contractility, assessed by the calculation of % 
FS (Fig. 3D). Finally, DM1 model flies fed with DMSO had a median 
survival of only 28 days, while survival of DM1 flies fed with 
daunorubicin increased up to 40 days, which is close to the 47 days of 
median survival in control flies with no CTG repeats (Fig. 3F). As a 
control to discard a general effect of daunorubicin on flies’ survival, 
we fed flies expressing GFP in cardiac muscle with daunorubicin and 
analyzed their survival curves. Daunorubicin had no effect on the 
survival of these control flies (Fig. S3A). In conclusion, daunorubicin 
improved all the cardiac parameters of DM1 flies, as well as their 
median survival, but did not affect control flies. 
 
Daunorubicin redistributed Mbl from foci in Drosophila 
cardiomyocytes and rescued Mbl-dependent splicing 
defects 
To observe the effect of daunorubicin on Mbl distribution, we 



























Fig. 3. All DM1 cardiac alterations were rescued by daunorubicin. 
(A-E) Alterations in HP, SI, DI, %FS and AI found in model flies fed with DMSO 
(‘D’) were significantly rescued to nearly normal conditions by treatment  
with daunorubicin hydrochloride (Dauno) (n=14 to 29). (F) Median survival was 
also rescued by daunorubicin treatment (n≈50). ***P<0.001, **P<0.01, 
*P<0.05 (Student’s t-test). 
 
 
RNA foci and Mbl, respectively, in hearts of flies expressing 
expanded CUG repeats fed with 1 μM daunorubicin. As previously 
reported (Chakraborty et al., 2015), ribonuclear foci containing Mbl 
were present in the cardiac muscle nuclei of flies expressing CUG 
repeats. In cardiomyocytes of model flies fed with daunorubicin, we 
did not observe ribonuclear foci and Mbl was found 
homogeneously distributed in the nuclei (Fig. 4). As control, 
quantitative reverse transcription PCR (RT-qPCR) indicates that 
Mbl expression was not modified in DM1 flies treated with 
daunorubicin compared to DM1 flies fed or not  with  DMSO 
(Fig. 5A). 
Next, we studied Mbl-dependent splicing events to test whether 
Mbl redistribution in the nuclei was enough to correct mis-splicing. 
Notably, daunorubicin corrects both Serca exon 13 (Fig. 5B) and 
formin (Fhos) exon 16′ (Fig. 5C,D) splicing events, which are Mbl- 
dependent events altered in heart of DM1 flies (Cerro-Herreros   
et al., 2017). These data show that daunorubicin induces Mbl 
redistribution in the nuclei enough to correct Mbl-dependent 
splicing events. In contrast, in flies expressing GFP in 
cardiomyocytes as controls, daunorubicin treatment did not alter 
the pattern of these splicing events, thus ruling out a general effect 
of daunorubicin on splicing regulation (Fig. S3B,C). 
 
Daunorubicin interacts directly with CUG RNA repeats, 
modifying its stability 
To test whether daunorubicin exerts its correcting effect by direct 
interaction with the CUG RNA, and competition with MBNL1, we 
performed electrophoretic mobility shift assay and analyzed the 
binding of recombinant GST-MBNL1 to internally labelled in vitro 
transcribed RNAs containing ten CUG repeats in the presence of 
increasing amounts of daunorubicin (Fig. 6A,B). According to 
these experiments, the quantity of daunorubicin needed to release 
half of MBNL bound to CUG 10× (in vitro IC50) would be 100 nM. 
We also used differential scanning fluorimetry (DSF) to monitor 
CUG-expanded RNA thermodynamics in the presence of growing 
concentrations of daunorubicin. The effect of a compound on 
RNA stability can be measured by DSF because RNA undergoes 




Fig. 4. Daunorubicin abrogates foci presence and redistributes Mbl in Drosophila cardiomyocytes. Representative confocal images of cardiomyocytes of 
Drosophila DM1 flies fed with daunorubicin (A-D) or DMSO (E-H). Acquisition settings were the same for images taken within the same channel. Double in situ 
hybridization and immunodetection of CUG RNA (red) and Mbl (green) showed that Mbl was dispersed in the nuclei of cardiomyocytes of flies fed with 




























Fig. 5. In model flies fed with daunorubicin, Mbl transcript levels were not 
modified but Mbl-dependent splicing defects were restored. (A) RT-qPCR to 
assess Mbl expression levels relative to endogenous tubulin in cardiomyocytes 
showed that it was not modified by administration of daunorubicin. (B) RT-qPCR 
results of Serca exon 13 expression relative to Rp49 confirmed a significant 
rescue of the expression of this exon in model flies fed with daunorubicin. 
(C) Semi-quantitative PCR to assess inclusion of Fhos exon 16′ in model flies fed 
with DMSO or daunorubicin. Rp49 transcripts were detected as endogenous 
control. Quantification of percentage of exon inclusion (see D for a representative 
result) confirmed an improvement of Fhos mis-splicing in model flies fed with 
daunorubicin. *P<0.05, ***P<0.001 (Student’s t-test). 
 
 
upon thermal unfolding. These transitions are accompanied by 
increased availability of binding sites for the single-stranded-RNA- 
specific dye RiboGreen. In this type of assay, the initial fluorescence 
originates from binding of the dye to unstructured, single-stranded, 
binding-competent regions of the RNA. After an initial decrease, 
the fluorescence increases because of destabilization of compact 
RNA structures, thereby becoming competent to bind the dye and 
achieving a point of maximal fluorescence. Then, this process 
reverses due to the formation of secondary structures indicated by a 
decrease in the binding affinity of the dye until RNA is completely 
folded (Silvers et al., 2015). We represented the fluorescence 
intensity and the first derivatives of normalized fluorescence of 
RiboGreen with an RNA probe containing 12 repeats of CUG 
versus temperature in the presence of concentrations of 
daunorubicin ranging from 0.1 to 2 µM and observed  an 
important decrease in the maximal fluorescence and a shift of the 
melting towards higher temperatures with growing concentrations 
of daunorubicin (Fig. 6C,D). These data are coherent with the 
known intercalation of daunorubicin with double-stranded RNA 
(Doskocil and Fric, 1973) and suggest that daunorubicin stabilizes a 
double-stranded hairpin conformation of the CUG RNA repeats, 
resulting in less available single-stranded binding sites for the 
RiboGreen dye. Extrapolating these results to the binding of 
MBNL1 to expanded CUG repeats, it is likely that daunorubicin, by 
stabilizing a double-stranded hairpin RNA structure, limits the 
accessibility of MBNL1 to free single-stranded YGC RNA motifs 
(Lambert et al., 2014; Delorimier et al., 2014; Park et al., 2017). 
Given the ability of daunorubicin to intercalate within the DNA 
and thus to alter transcription and replication, we also quantified 
the expression level and length of expanded CTG repeats. PCR 
amplification revealed that the DNA region including the CTG 
repeats had the same length (1178 bp) in DM1 flies fed with either 
DMSO or daunorubicin (Fig. 6E). Furthermore, quantitative RT- 
qPCR indicated no changes of CTG transgene expression in DM1 
flies fed with DMSO compared to daunorubicin treatment (Fig. 6F). 
These data support a mechanism of action based on daunorubicin’s 
direct interaction with CUG RNA decreasing MBNL accessibility 
to the repeats, rather than a modification of the mutant DNA 
expression or length. 
 
DISCUSSION 
We previously reported alterations of different heart functions, 
including heart rate, rhythmicity, SI, DI and %FS in flies expressing 
pure expanded CUG repeats (Chakraborty et al., 2015). The 
relevance of our model of heart dysfunction in DM1 was supported 
by the similarities between the cardiac phenotype in DM1 model 
flies and those documented in DM1 patients. Here, we show that the 
sole expression of Mbl can rescue all these cardiac parameters to 
their normal values, except the DI, which was not altered by MblC 
overexpression. These results support the involvement of Mbl in the 
cardiac dysfunction in DM1 and the therapeutic potential of its 
overexpression. Our data are consistent with the compound loss of 
Mbnl1 and Mbnl2 that evokes DM1-like cardiac phenotypes in mice 
(Lee et al., 2013). Furthermore, we identified pharmacological 
compounds reducing MBNL1 sequestration by expanded CUG 
repeats and found that one of these drugs, daunorubicin 
hydrochloride, achieved a complete rescue of cardiac parameters, 
including survival, arrhythmia, %FS and HP, with an increase of 
both DI and SI in DM1 flies. The fact that DI was suppressed by 
daunorubicin and not by MblC suggested that either other Mbl 
isoforms are required for a complete rescue of Mbl function in heart 
or that daunorubicin affects other Mbl-independent components, 
which might be involved in DI duration in DM1. Potential Mbl- 
independent activity of daunorubicin might be related to its ability to 
cause DNA damage. Daunorubicin belongs to the anthracyclines 
family, which has been used in curative and palliative treatment of 
several types of cancer (Hande, 1998; Gewirtz, 1999). Although 
anthracyclines produce a wide range of biological reactions, their 
primary mechanism of tumour cytotoxicity has been ascribed to the 
inhibition of the topoisomerase II enzyme (Nielsen et al., 1996; 
Arcamone et al., 1997). Thus, anthracycline drugs may cause DNA 
damage such as fragmentation and single-strand breaks, which can 
influence microsatellite expanded repeat instability. Notably, 
treatment of cells with 1, 2 and 5 mg/ml (1.8 μM, 3.54 μM and 
8.86 μM, respectively) of doxorubicin, a 14-hydroxylated version of 
daunorubicin, causes some reduction of CTG repeat length (Hashem 
et al., 2004). However, we assessed CTG repeat length in 1 µM 
daunorubicin-treated flies and found no alterations. Of interest, the 
normal dosage used for daunorubicin hydrochloride in adults under 
60 years of age is 45 mg/m2 once a day on days 1, 2 and 3 for the first 
course. This dosage would involve a concentration of 2 µM 
daunorubicin. DM1 flies fed with 1 µM daunorubicin throughout 
their lifespan have improved survival in comparison to DM1 flies fed 
with DMSO, suggesting that the cumulative daunorubicin doses 
achieved were not overtly toxic at this concentration. 
Daunorubicin also interacts with double-stranded RNA 
(Doskocil and Fric, 1973). Our results indicate that daunorubicin 
directly interacts with expanded CUG RNA repeats and impairs 
binding of MBNL1 to these repeats, thus promoting MBNL1 
release from CUG RNA foci in DM1 cells, as well as in DM1 
Drosophila cardiomyocytes. Importantly, this reduced depletion of 
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Fig. 6. Daunorubicin binds directly to CUG RNA, stabilizes 
CUG RNA structure in vitro and does not modify the CUG- 
repeat expression level or length. (A) Gel-shift assays of 10 nM 
of purified bacterial recombinant GST-MBNL1 with 10 pM 
(2000 CPM) of uniformly [alphaP32] internally labelled in vitro 
transcribed RNAs containing 10 CUG repeats in the presence of 
increasing amounts of daunorubicin. (B) Gel-shift quantification 
with IC50 represented by the red lines. (C) Normalized 
fluorescence intensity and (D) first derivatives of RiboGreen 
fluorescence versus temperature at different daunorubicin 
concentrations. Grey vertical bars mark the minimum (57.8°C) 
and maximum (65.9°C) melting temperatures. (E) Agarose gel 
showing CTG repeat length inserted in the genomic DNA of DM1 
flies fed with either DMSO or daunorubicin. MWM, molecular 
weight marker. (F) Bar graph represents means±s.e.m. of SV40 
expression (contained in the CTG transgene) relative to tubulin. 
According to E and F, the effect of daunorubicin is not mediated 
by a reduction in the CTG repeat length or expression level in 















flies. Overall, these results support a key role of Mbl protein 
sequestration in the cardiac dysfunctions observed in DM1. 
Daunorubicin should be taken cautiously because of the 
genotoxic effects of this compound in long-term treatments. 
However, as proof of concept, our results suggest that inhibiting 
MBNL1 binding to expanded CUG repeats is a valid strategy to 
rescue cardiac phenotypes in DM1. 
This study supports an important role for Mbl sequestration in the 
cardiac dysfunctions induced by expanded CUG repeats in DM. 
Furthermore, we uncovered a new FDA-approved compound with 
the ability of dissolving foci and competing MBNL1 away from 
CUG RNA foci. However, given the toxicity profile of 
daunorubicin, subsequent studies on murine models of the disease 
would be required to determine whether it could be considered as a 
suitable therapeutic approach for DM1. 
 
MATERIALS AND METHODS 
Drosophila strains 
The cardiomyocyte-specific driver GMH5-Gal4; UAS-GFP was kindly 
provided by Dr Bodmer (Sanford Burham Institute, CA). Generation of 
CUG(250)× and UAS-MblC flies was previously described (Chakraborty 
et al., 2015; García-Casado et al., 2002). UAS-GFP strain was obtained 
from the Bloomington Drosophila Stock Center (Indiana University, 
Bloomington, IN). 
 
Compound                                           treatment 
Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a 
final concentration of 1 µM in 0.1% DMSO. The control group was fed with 
0.1% DMSO in standard food. Flies were transferred every 3 days to new 
fresh food media, with or without compound, for the duration of their whole 
lifespan in survival curve experiments or during 7 days in the case of the 
group used for cardiac analysis and immunofluorescence. 
Survival analyses 
For survival analyses, a minimum of 50 flies were included per group and 
the survival curves were obtained at 29°C. Scoring of death was done as 
previously described (Chakraborty et al., 2015; Cerro-Herreros et al., 2017). 
Cardiac                     physiological                     analysis 
For the physiological analysis, female flies were collected just after eclosion 
and were maintained for 7 days at 29°C in compound and DMSO- 
supplemented food. For the heart beat recordings, semi-intact heart 
preparations were made as previously described (Magny et al., 2013; 
Cerro-Herreros et al., 2017; Chakraborty et al., 2015). A Leica microscope, 
connected to an ORCA Flash (Hamamatsu) high-speed digital camera was 
used to take 20 s recordings at a minimum speed of 150 frames/s. Different 
cardiac parameters were measured using SOHA software (Ocorr et al., 
2014). 
Alternative                  splicing                  quantification 
For each biological replicate, total RNA was extracted using Qiazol (Qiagen) 
from at least 20 female hearts. One microgram of RNA was digested with 
DNase I (Invitrogen) and retro-transcribed with SuperScript II (Invitrogen) 
using random hexanucleotides. To analyze Fhos exon 16′ inclusion, 20 ng 
of cDNA was used in a standard semi-quantitative PCR reaction with GoTaq 
polymerase. Serca exon 13 expression, SV40 to measure repeats expression, 
and Mbl expression were checked with RT-qPCR as previously described 
(Cerro-Herreros et al., 2017, 2016). 
 
Repeat number detection 
To confirm the number of repeats in the flies fed with the compound or 
DMSO, 40 ng of genomic DNA was used as a template for the PCR 
amplification as described previously (Chakraborty et al., 2015). The region 
amplified by the primers includes long repeats (750 bp) and 428 bp of the 
CTG (250)× plasmid. PCR amplification was performed under the 
following conditions: 95°C for 2 min, followed by 30 cycles of 98°C for 
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The PCR products were analyzed by electrophoresis at 110 V in 1.5% 
agarose gels. 
 
DM1 myoblast culture and staining 
Primary human myoblast cells originating from muscle biopsies of 
genetically confirmed DM1 patients were maintained at 37°C with 10% 
CO2 in skeletal muscle cell basal media with supplements (PromoCell, 
Heidelberg, Germany) and 10% fetal calf serum. For myoblast 
differentiation, cells were maintained for 4 days in DMEM with 2% fetal 
calf serum, the drug was added for 16 h and then assayed for CUG RNA foci 
and MBNL1 localization by classic RNA FISH immunofluorescence. Glass 
coverslips containing plated cells were fixed in PFA 4% for 15 min and 
washed two times with PBS. The coverslips or slides were incubated for 
10 min in PBS plus 0.5% Triton X-100 and washed three times with PBS 
before pre-hybridization in 40% DMSO, 40%  formamide,  10%  BSA 
(10 mg/ml), 2× SCC for 30 min. The coverslips or slides were hybridized 
for 2 h in 40% formamide, 10% DMSO, 2× SCC, 2 mM vanadyl 
ribonucleoside, 60 μg/ml tRNA, 30 μg/ml BSA plus 0.75 μg CAG8x-Cy3 
DNA oligonucleotide probe (Sigma). Following FISH, the coverslips or 
slide were washed twice successively in 2× SCC/50% formamide, in 2× 
SCC and in PBS. The coverslips or slides were incubated for 2 h with 
primary polyclonal antibody against MBNL1 (1/100 dilution, gift of Prof. 
Charles Thornton, University of Rochester Medical Center, Rochester, NY). 
Slides or coverslips were washed twice with PBS before incubation with a 
goat anti-rabbit secondary antibody conjugated with Alexa Fluor 488 (1/500 
dilution, #A32731, Fisher Scientific SA) for 60 min, incubated for 10 min 
in 2× SCC/DAPI (1/10,000 dilution) and rinsed twice in 2× SSC before 
mounting in Pro-Long media (Molecular Probes). Slides were examined 
using a fluorescence microscope (Leica). 
 
Foci quantification in DM1 fibroblasts 
Immortalized (hTERT) human DM1 (1300 CTG repeats) skin fibroblasts 
conditionally expressing MyoD were provided by D. Furling’s laboratory in 
the Institute of Myologie, Paris. Fibroblast cells were grown in Dulbecco’s 
modified Eagle medium (DMEM) with 4.5 g/l glucose, 1% penicillin and 
streptomycin (P/S), and 10% fetal bovine serum (FBS; Sigma). Fibroblasts 
were aliquoted into 96-well plates (1.0×104 cells per well), incubated with 
daunorubicin or DMSO (48 h) and fixed in 4% PFA for 10 min at room 
temperature followed by several washes in 1× PBS. Fixed cells were 
incubated in pre-hybridization buffer (2× SSC, 30% deionized formamide) 
for 10 min at room temperature and hybridized with Cy3-(CAG)7-Cy3- 
labelled probe diluted 1:500 in hybridization buffer [40% formamide, 2× 
SSC, 0.2% BSA, 10% dextran sulfate, 2 mM ribonucleoside-vanadyl 
complex, 10% tRNA (10 mg/ml) and 10% herring sperm] for 2 h at 37°C. 
After hybridization, cells were washed twice with pre-hybridization buffer 
for 15 min at 45°C, washed twice with 0.5× SSC for 5 min at 37°C, washed 
with 1× PBS for 15 min at room temperature, incubated with Hoechst 33342 
(5 mg/ml) diluted 1:2000 in 1× PBS for 20 min at room temperature, and 
mounted with 20% Mowiol. Images were taken and analyzed using an IN 
Cell Analyzer 2200 Imaging System. 
 
Immunofluorescence          analysis           in           flies 
For immunofluorescence analysis in Drosophila cardiomyocytes, 7-day-old 
dissected female fly hearts were fixed for 20 min in 4% paraformaldehyde 
and washed in PBT (PBS containing 0.3% Triton X-100) before staining. 
Mbl staining and FISH to detect ribonuclear CUG foci were performed as 
previously described (Llamusi et al., 2012). All the confocal images were 
taken with an Olympus FV1000 microscope. 
 
Differential scanning fluorimetry (DSF) 
DSF experiments were performed to understand the interaction of 
daunorubicin with the double-stranded CUG hairpin using DSF technique 
(Silvers et al., 2015). The experiment was performed using a StepOnePlus 
Real-Time PCR system (Life Technologies) with the melting curve software 
to measure the fluorescence intensity. A MicroAmp® Fast Optical 96-well 
plate (Life Technologies) was used with 50 μl of solution per well. The 
RiboGreen dye was used at a final concentration of 300 nM, whereas the 
synthetic double-stranded CUG RNA (12× CUG) was used at a final 
concentration of 600 nM. For each compound (in this case daunorubicin and 
DMSO), four technical replicates were performed and, for daunorubicin, 
eight different concentrations ranging from 0.1-2 μM were used. Sodium 
cacodylate buffer was used at pH 6.1, which is essential for experiments 
using RNA. During the DSF experiment, the temperature was increased 
from 4 to 95°C at an increment of 0.2°C with an equilibration time of 5 s at 
each temperature prior to measurement. The Excel sheets containing 
melting temperature, and normalized and derivative fluorescence data were 
exported into GraphPad Prism 5 software for further analysis and generation 
of graphics. 
 
Electrophoretic mobility shift assay 
10 pM (2000 CPM) of labelled CUG 10× RNA was incubated at 90°C for 
5 min in binding buffer [BB; 0.75 mM MgCl2, 50 mM Tris-HCl ( pH 7.0), 
75 mM NaCl, 37.5 mM KCl, 5.25 mM DTT, 0.1 mg/ml BSA, 0.1 mg/ml 
Bulk tRNA] and allowed to cool to room temperature. After cooling, RNasin 
was added to a final concentration of 0.4 U/μl. GST-MBNL1Δ101 was then 
added and the mixture was incubated on ice for 20 min. The solution 
mixture was loaded onto a non-denaturing 6.0% (w/v) polyacrylamide gel 
(acrylamide/bisacrylamide, 40:1, w/w) containing 0.5× TBE [1× TBE is 
90 mM Tris-base, 89 mM boric acid and 2 mM EDTA ( pH 8.0)], which 
had been pre-electrophoresed at 110 V for 20 min at 4°C. The gel was 
electrophoresed at 110 V at 4°C for 3 h, then dried and exposed to a 
phosphorimager screen and imaged using a Typhoon 9410. 
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